Phreesia (PHR) 10-K 23 Mar 23 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jan. 31, 2023	Mar. 17, 2023	Jul. 31, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jan. 31, 2023
Current Fiscal Year End Date	--01-31
Document Transition Report	false
Entity File Number	001-38977
Entity Registrant Name	PHREESIA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2275479
Entity Address, Address Line One	1521 Concord Pike
Entity Address, Address Line Two	Suite 301 PMB 221
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19803
City Area Code	888
Local Phone Number	654-7473
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	PHR
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 1,157,351,642
Entity Common Stock, Shares Outstanding (in shares)		53,355,050
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s Definitive Proxy Statement relating to its 2023 Annual Meeting of Stockholders to be filed hereafter are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
Amendment Flag	false
Entity Central Index Key	0001412408
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY

Audit Information

Audit Information	12 Months Ended
	Jan. 31, 2023
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Location	Pittsburgh, PA
Auditor Firm ID	185

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Current:
Cash and cash equivalents	$ 176,683	$ 313,812
Settlement assets	22,599	19,590
Accounts receivable, net of allowance for doubtful accounts of $1,053 and $863 as of January 31, 2023 and 2022, respectively	51,394	40,262
Deferred contract acquisition costs	1,056	1,642
Prepaid expenses and other current assets	10,709	11,043
Total current assets	262,441	386,349
Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively	21,670	34,645
Capitalized internal-use software, net of accumulated amortization of $37,236 and $31,139 as of January 31, 2023 and 2022, respectively	35,150	17,643
Operating lease right-of-use assets	569	2,337
Deferred contract acquisition costs	1,754	2,437
Intangible assets, net of accumulated amortization of $2,549 and $1,178 as of January 31, 2023 and 2022, respectively	11,401	12,772
Deferred tax asset	81	515
Goodwill	33,736	33,621
Other assets	3,255	4,157
Total Assets	370,057	494,476
Current:
Settlement obligations	22,599	19,590
Current portion of finance lease liabilities and other debt	5,172	5,821
Current portion of operating lease liabilities	934	1,281
Accounts payable	10,836	5,119
Accrued expenses	21,810	20,128
Deferred revenue	17,688	16,493
Total current liabilities	79,039	68,432
Long-term finance lease liabilities and other debt	2,725	7,423
Operating lease liabilities, non-current	349	1,276
Long-term deferred revenue	125	65
Total Liabilities	82,238	77,196
Commitments and contingencies (Note 11)
Stockholders’ Equity:
Common stock, $0.01 par value—500,000,000 shares authorized as of both January 31, 2023 and 2022; 54,187,172 and 52,095,964 shares issued as of January 31, 2023 and 2022, respectively	542	521
Additional paid-in capital	926,957	860,657
Accumulated deficit	(606,084)	(429,938)
Treasury stock, at cost, 971,236 and 301,003 shares as of January 31, 2023 and 2022, respectively	(33,596)	(13,960)
Total Stockholders’ Equity	287,819	417,280
Total Liabilities and Stockholders’ Equity	$ 370,057	$ 494,476

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 1,053	$ 863
Accumulated depreciation and amortization, property and equipment	59,847	53,321
Accumulated amortization of capitalized internal-use software	37,236	31,139
Accumulated amortization of intangible assets	$ 2,549	$ 1,178
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	54,187,172	52,095,964
Treasury stock (in shares)	971,236	301,003

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Revenue:
Total revenue	$ 280,910	$ 213,233	$ 148,677
Expenses:
Cost of revenue (excluding depreciation and amortization)	58,944	42,669	23,461
Payment processing expense	50,323	38,719	28,925
Sales and marketing	151,263	106,421	42,972
Research and development	91,244	52,265	22,622
General and administrative	80,384	68,674	40,460
Depreciation	17,988	14,985	9,770
Amortization	7,316	6,317	6,138
Total expenses	457,462	330,050	174,348
Operating loss	(176,552)	(116,817)	(25,671)
Other (expense) income, net	(175)	(78)	1
Interest income (expense), net	1,064	(1,084)	(1,573)
Total other income (expense), net	889	(1,162)	(1,572)
Loss before provision for income taxes	(175,663)	(117,979)	(27,243)
Provision for income taxes	(483)	(182)	(49)
Net loss	$ (176,146)	$ (118,161)	$ (27,292)
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (3.36)	$ (2.37)	$ (0.69)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (3.36)	$ (2.37)	$ (0.69)
Weighted-average common shares outstanding - basic (in shares)	52,440,067	49,888,436	39,519,640
Weighted-average common shares outstanding - diluted (in shares)	52,440,067	49,888,436	39,519,640
Subscription and related services
Revenue:
Total revenue	$ 128,975	$ 95,514	$ 69,042
Payment processing fees
Revenue:
Total revenue	78,368	65,201	49,900
Network solutions
Revenue:
Total revenue	$ 73,567	$ 52,518	$ 29,735

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated deficit	Treasury stock
Beginning balance, stockholders' equity (in shares) at Jan. 31, 2020		36,610,763
Beginning balance, stockholders' equity at Jan. 31, 2020	$ 101,865	$ 366	$ 386,383	$ (284,485)	$ (399)
Stockholders’ equity
Net loss	(27,292)			(27,292)
Stock-based compensation expense	$ 13,489		13,489
Exercise of stock options and vesting of restricted stock units (in shares)	2,216,368	2,459,782
Exercise of stock options and vesting of restricted stock units	$ 5,300	$ 25	5,275
Issuance of common stock, net of issuance costs (in shares)		5,750,000
Issuance of common stock, net of issuance costs	174,510	$ 57	174,453
Cashless exercise of common stock warrants (in shares)		60,338
Cashless exercise of common stock warrants	0	$ 1	(1)
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings	(4,566)				(4,566)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2021		44,880,883
Ending balance, stockholders' equity at Jan. 31, 2021	263,306	$ 449	579,599	(311,777)	(4,965)
Stockholders’ equity
Net loss	(118,161)			(118,161)
Stock-based compensation expense	$ 29,668		29,668
Exercise of stock options and vesting of restricted stock units (in shares)	1,439,186	1,997,551
Exercise of stock options and vesting of restricted stock units	$ 4,143	$ 20	4,123
Issuance of common stock for employee stock purchase plan (in shares)		42,530
Issuance of common stock for employee stock purchase plan	1,506		1,506
Issuance of common stock, net of issuance costs (in shares)		5,175,000
Issuance of common stock, net of issuance costs	245,813	$ 52	245,761
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings	(8,995)				(8,995)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2022		52,095,964
Ending balance, stockholders' equity at Jan. 31, 2022	417,280	$ 521	860,657	(429,938)	(13,960)
Stockholders’ equity
Net loss	(176,146)			(176,146)
Stock-based compensation expense	$ 52,506		52,506
Exercise of stock options and vesting of restricted stock units (in shares)	311,743	1,626,123
Exercise of stock options and vesting of restricted stock units	$ 1,531	$ 16	1,515
Issuance of common stock for employee stock purchase plan (in shares)		162,154
Issuance of common stock for employee stock purchase plan	3,472	$ 2	3,470
Issuance of stock for share-settled bonus awards (in shares)		302,931
Issuance of stock for share-settled bonus awards	8,812	$ 3	8,809
Treasury stock from vesting of restricted stock units - satisfaction of tax withholdings	(19,636)				(19,636)
Ending balance, stockholders' equity (in shares) at Jan. 31, 2023		54,187,172
Ending balance, stockholders' equity at Jan. 31, 2023	$ 287,819	$ 542	$ 926,957	$ (606,084)	$ (33,596)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	12 Months Ended
	Jan. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 290

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Operating activities:
Net loss	$ (176,146)	$ (118,161)	$ (27,292)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	25,304	21,302	15,908
Non-cash stock-based compensation expense	58,775	36,144	13,489
Amortization of deferred financing costs and debt discount	310	288	389
Cost of Phreesia hardware purchased by customers	1,598	672	762
Deferred contract acquisition costs amortization	1,696	2,211	2,025
Non-cash operating lease expense	1,768	1,004	1,766
Change in fair value of contingent consideration liabilities	0	258	0
Deferred tax asset	434	143	(65)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(11,132)	(10,216)	(6,619)
Prepaid expenses and other assets	250	(7,192)	(1,600)
Deferred contract acquisition costs	(427)	(3,349)	(1,652)
Accounts payable	4,774	2,881	(3,821)
Accrued expenses and other liabilities	2,720	(2,983)	6,004
Lease liability	(1,302)	(1,060)	(1,786)
Deferred revenue	1,255	3,348	5,382
Net cash (used in) provided by operating activities	(90,123)	(74,710)	2,890
Investing activities:
Acquisitions, net of cash acquired	0	(34,423)	(6,510)
Capitalized internal-use software	(21,471)	(12,385)	(7,334)
Purchases of property and equipment	(4,732)	(18,420)	(11,241)
Net cash used in investing activities	(26,203)	(65,228)	(25,085)
Financing activities:
Proceeds from issuance of common stock in equity offerings, net of underwriters' discounts and commissions	0	245,813	174,800
Proceeds from issuance of common stock upon exercise of stock options	1,603	4,889	4,385
Treasury stock to satisfy tax withholdings on stock compensation awards	(19,383)	(8,995)	(4,965)
Payment of offering costs	0	0	(290)
Proceeds from employee stock purchase plan	3,321	1,979	0
Insurance financing agreement	0	0	2,009
Finance lease payments	(5,731)	(4,267)	(2,630)
Principal payments on financing agreements	(216)	(1,039)	(1,691)
Debt issuance costs and facility fees	(397)	(125)	(294)
Financing payments of acquisition-related liabilities	0	(3,286)	0
Payments of revolving line of credit	0	0	(20,663)
Net cash (used in) provided by financing activities	(20,803)	234,969	150,661
Net (decrease) increase in cash and cash equivalents	(137,129)	95,031	128,466
Cash and cash equivalents—beginning of year	313,812	218,781	90,315
Cash and cash equivalents—end of year	176,683	313,812	218,781
Supplemental information of non-cash investing and financing activities:
Right-of-use assets recorded in exchange for operating lease liabilities	0	81	4,359
Property and equipment acquisitions through finance leases	526	7,394	8,885
Capitalized software acquired through vendor financing	0	0	174
Purchase of property and equipment and capitalized software included in accounts payable and accrued liabilities	2,345	1,124	3,359
Cashless transfer of term loan and related accrued fees into increase in debt balance	0	0	20,257
Cashless transfer of lender fees through increase in debt balance	0	0	406
Receivables for cash in-transit on stock option exercises	97	169	915
Cashless exercise of common stock warrants	0	0	3,060
Capitalized stock based compensation	1,372	489	0
Issuance of stock to settle liabilities for stock-based compensation	12,284	0	0
Cash paid for:
Interest	763	802	1,465
Income taxes	$ 39	$ 49	$ 64

Background and liquidity

Background and liquidity	12 Months Ended
	Jan. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and liquidity	Background and liquidity (a) Background Phreesia, Inc. (the "Company") is a leading provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through the SaaS-based technology platform (the "Phreesia Platform" or "Platform"), the Company offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration and payments. The Company’s Platform also provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. In connection with the patient intake and registration process, Phreesia offers its healthcare services clients the ability to lease tablets ("PhreesiaPads") and on-site kiosks ("Arrivals Kiosks") along with their monthly subscription. The Company was formed in May 2005. During the fiscal year ended January 31, 2023, the Company ceased using its Raleigh, North Carolina office as its principal executive offices. b) Liquidity Since the Company commenced operations, it has not generated sufficient revenue to meet its operating expenses and has continued to incur significant net losses. To date, the Company has primarily relied upon the proceeds from issuances of common stock, debt and preferred stock to fund its operations as well as sales of Company products and services in the normal course of business. Management believes that net losses and negative cash flows will continue for at least the next year. On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, the Company transferred a substantial portion of its cash and cash equivalents from SVB to other financial institutions. The Company had total cash and cash equivalents of approximately $170 million as of March 10, 2023. On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of actions taken by the Company to move a substantial portion of its cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, the Company has determined that all of its cash and cash equivalents continue to be available for use by the Company. The Company is also party to the Second Amended and Restated Loan and Security Agreement with SVB, as amended by the First Loan Modification Agreement (the “Third SVB Facility”), which contains certain restrictive covenants including a covenant that limits the Company's ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of the Company’s cash and cash equivalents from SVB to other financial institutions, the Company obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit the Company to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as the company remains in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted the Company's financial position or its operations. See Note 6 - Finance Leases and Other Debt and Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing. Management believes that the Company’s cash and cash equivalents at January 31, 2023, along with cash generated in the normal course of business, are sufficient to fund its operations for at least the next 12 months.

Basis of presentation

Basis of presentation	12 Months Ended
	Jan. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Basis of presentation(a) Consolidated Financial Statements The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company"). (b) Fiscal year The Company’s fiscal year ends on January 31. References to fiscal 2023, 2022 and 2021 refer to the fiscal years ended January 31, 2023, 2022 and 2021, respectively. (c) Network solutions revenue During the year ended January 31, 2023, the Company relabeled its Life sciences category of revenue presented on its Consolidated Statements of Operations to Network solutions revenue. The Company's Network solutions revenue includes fees from life sciences and payer clients for delivering direct communications to help activate, engage and educate patients about topics critical to their health using the Phreesia Platform. Prior to the year ended January 31, 2023, the Company's Network solutions revenue was generated by its life sciences clients. There have been no changes to previously reported revenues.

Summary of significant accounti

Summary of significant accounting policies	12 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies(a) Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets. (b) Revenue recognition The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers , as well as for additional details about the Company's products and service lines. (c) Concentrations of credit risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two The Company’s customers are primarily physician’s offices and other healthcare services organizations located in the United States as well as pharmaceutical companies. The Company did not have any individual customers that represented more than 10% of total revenues for the years ended January 31, 2023 and January 31, 2022. As of both January 31, 2023 and January 31, 2022, the Company had receivables from at least one entity that accounted for at least 10% of total accounts receivable. See Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing. (d) Risks and uncertainties The Company is subject to a variety of risk factors, including the economy, data privacy and security laws and government regulations. Additionally, the Company is subject to other risks associated with the markets in which it operates including reliance on third-party vendors, partners, and service providers. Certain of the Company's service providers, including certain third-party software developers, are located in international locations subject to warfare and/or political and economic instability, such as Russia, Ukraine and India. As with any business, operation of the Company involves risk, including the risk of service interruption impacting the operations of the Company's business and the Company's customer’s facilities below expected levels of operation, shut downs due to the breakdown or failure of information technology and communications systems, changes in laws or regulations, political and economic instability, or catastrophic events such as fires, earthquakes, floods, explosions, global health concerns such as pandemics or other similar occurrences affecting the delivery of our productions and services. The occurrence of any of these events could significantly reduce or eliminate revenues generated, or significantly increase the expenses of the Company's operations, adversely impacting the Company’s operating results and the Company's ability to meet the Company's obligations and commitments. See Note 6 - Finance leases and other debt and Note 11 - Commitments and Contingencies, for a summary of our contractual commitments as of January 31, 2023. See Note 17 - Subsequent Event for the impact of SVB's closure on the Company's cash and cash equivalents, liquidity and sources of financing. (e) Cost of revenue (excluding depreciation and amortization) Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third-party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation. (f) Payment processing expense Payment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways. (g) Sales and marketing Sales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred. Advertising expense was $2,634, $4,007 and $558 for the fiscal years ended January 31, 2023, 2022 and 2021, respectively. (h) Research and development Research and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period. (i) General and administrative General and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead. (j) Depreciation Depreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements. (k) Amortization Amortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets. (l) Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents. (m) Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one two (n) Settlement obligations Settlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor. (o) Accounts receivable Accounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted. As of January 31, 2023 and 2022, the Company has reserved $1,053 and $863, respectively, for the allowance for doubtful accounts. Account receivable also includes unbilled accounts receivable (see Contract Balances in Note 5). (p) Property and equipment Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations. (q) Capitalized internal-use software The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software . These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three (r) Business combinations The Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations. When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations. (s) Goodwill and intangible assets Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount. All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives. (t) Long-lived assets Long-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented. (u) Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes . ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure. The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes. (v) Segment information Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements. (w) Stock-based compensation The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718 , Compensation — Stock Compensation , which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria. The fair value of stock options is estimated at the time of grant using the Black-Scholes option pricing model, which requires the use of inputs and assumptions such as the exercise price of the option, expected term, risk-free interest rate, expected volatility and dividend yield, and the value of the Company's common stock (which is estimated for awards granted prior to our IPO). The Company does not estimate forfeitures in recognizing stock-based compensation expense. The fair value of the RSUs is equal to the fair value of the Company's common stock on the grant date of the award. The fair value of market-based PSUs is estimated at the time of grant using a Monte Carlo simulation which compares Phreesia's projected total shareholder return ("TSR") to the projected TSR of the Russell 3000 Index (the "Peer Group") and estimates the value of shares to be issued based on the vesting conditions of the PSUs. The Monte Carlo simulation requires the use of inputs and assumptions such as the grant-date closing stock price, simulation, expected volatility, correlation coefficient to the Russell 3000 Index, risk-free interest rate and dividend yield. See Note 8 - Equity-Based Compensation, for additional information on stock-based compensation. (x) Fair value of financial instruments Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. (y) Equity offering costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations. (z) Foreign currency The Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net. (aa) New accounting pronouncements Impact of recently adopted accounting pronouncements During the year ended January 31, 2023, the Company did not adopt any accounting pronouncements. Recent accounting pronouncements not yet adopted There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.

Composition of certain financia

Composition of certain financial statement captions	12 Months Ended
	Jan. 31, 2023
Composition Of Certain Financial Statement [Abstract]
Composition of certain financial statement captions	Composition of certain financial statement captions (a) Accrued expenses Accrued expenses at January 31, 2023 and 2022 are as follows: January 31, 2023 2022 Payroll-related expenses and taxes $ 10,345 $ 10,780 Payment processing fees liability 4,796 3,502 Acquisition-related liabilities 96 96 Tax liabilities 1,491 2,093 Information technology services 2,249 1,266 Other 2,833 2,391 Total $ 21,810 $ 20,128 (b) Property and equipment Property and equipment at January 31, 2023 and 2022 are as follows: Useful life January 31, 2023 2022 PhreesiaPads and Arrivals Kiosks 3 $ 17,932 $ 26,387 Computer equipment 3 54,485 53,957 Computer software 3 to 5 8,571 5,311 Hardware development 3 529 1,024 Furniture and fixtures 7 — 539 Leasehold improvements 2 — 748 Total property and equipment $ 81,517 $ 87,966 Less accumulated depreciation (59,847) (53,321) Property and equipment — net $ 21,670 $ 34,645 Depreciation expense related to property and equipment amounted to $17,988, $14,985 and $9,770 for the fiscal years ended January 31, 2023, 2022 and 2021, respectively. Assets acquired under finance leases included in computer equipment were $27,813 and $27,310 at January 31, 2023 and 2022, respectively. Accumulated amortization of assets under finance leases was $20,657 and $15,025 at January 31, 2023 and 2022, respectively. (c) Capitalized internal-use software For the fiscal years ended January 31, 2023, 2022 and 2021, the Company capitalized $23,604, $12,830 and $7,663 of costs related to the Phreesia Platform, respectively. During the fiscal years ended January 31, 2023, 2022 and 2021 amortization expense related to capitalized internal-use software was $5,945, $5,664 and $5,884, respectively. (d) Intangible assets and goodwill The following presents the details of intangible assets as of January 31, 2023 and January 31, 2022. Useful Life January 31, (years) 2023 2022 Acquired technology 5 $ 1,410 $ 1,410 Customer relationship 7 to 10 6,340 6,340 License 15 6,200 6,200 Total intangible assets, gross carrying value $ 13,950 $ 13,950 Less accumulated amortization (2,549) (1,178) Net carrying value $ 11,401 $ 12,772 The remaining useful life for acquired technology in years is 2.7 and 3.5 as of January 31, 2023 and 2022, respectively. The remaining useful life for customer relationships in years is 8.3 and 9.2 as of January 31, 2023 and 2022, respectively. The remaining useful life for the license to the Patient Activation Measure ("PAM"®) in years is 13.8 and 14.8 as of January 31, 2023 and 2022, respectively. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes. Amortization expense associated with intangible assets for the fiscal years ended January 31, 2023, 2022 and 2021 was $1,371, $653 and $254, respectively. The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2023: January 31, 2023 2024 $ 1,358 2025 1,273 2026 1,242 2027 949 Thereafter 6,579 Total $ 11,401 The following table presents a roll-forward of goodwill for the years ended January 31, 2022 and 2023: Balance at January 31, 2021 $ 8,307 Goodwill acquired during the year ended January 31, 2022 25,314 Balance at January 31, 2022 33,621 Measurement period adjustments to goodwill during the year ended January 31, 2023 115 Balance at January 31, 2023 $ 33,736 The Company did not record any impairments of goodwill during the years ended January 31, 2023, 2022 or 2021. Additions to goodwill during the year ended January 31, 2022 are net of a $96 measurement period adjustment for the QueueDr acquisition. Additions to goodwill during the year ended January 31, 2023 represent measurement period adjustments for the Insignia acquisition. Substantially all of the Company's goodwill is amortizable for tax purposes. (e) Accounts receivable Accounts Receivable as of January 31, 2023 and 2022 are as follows: January 31, 2023 2022 Billed $ 51,458 $ 40,733 Unbilled 989 392 Total accounts receivable, gross 52,447 41,125 Less accounts receivable allowances (1,053) (863) Total accounts receivable $ 51,394 $ 40,262 Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2023 and 2022: Balance, January 31, 2021 $ 699 Bad debt expense 212 Write-offs and adjustments (48) Balance, January 31, 2022 863 Bad debt expense 587 Write-offs and adjustments (397) Balance, January 31, 2023 $ 1,053 The Company’s allowance for doubtful accounts represents the current estimate of expected future losses based on prior bad debt experience as well as considerations for specific customers as applicable. The Company's accounts receivable are considered past due when they are outstanding past the due date listed on the invoice to the customer. The Company writes off accounts receivable and removes the associated allowance for doubtful accounts when the Company deems the receivables to be uncollectible. (f) Prepaid and other current assets Prepaid and other current assets as of January 31, 2023 and 2022 are as follows: January 31, 2023 2022 Prepaid software and business systems $ 3,426 $ 3,738 Prepaid data center expenses 2,389 3,230 Prepaid insurance 1,552 1,924 Other prepaid expenses and other current assets 3,342 2,151 Total prepaid and other current assets $ 10,709 $ 11,043 (g) Cloud computing implementation costs (h) Other (expense) income, net Other (expense) income, net for the year ended January 31, 2023 and 2022 was expense of $175 and $78, respectively, driven by foreign exchange losses, partially offset by other miscellaneous income.

Revenue and Contract Costs

Revenue and Contract Costs	12 Months Ended
	Jan. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue and Contract Costs	Revenue and Contract Costs The Company generates revenue primarily from providing an integrated SaaS-based software and payment platform for the healthcare industry. The Company derives revenue from subscription fees and related services generated from the Company’s healthcare services clients for access to the Phreesia Platform, payment processing fees based on patient payment volume, and fees from life sciences and payer clients for delivering direct communications to patients using the Phreesia Platform. The Company accounts for revenue from contracts with customers by applying the requirements of ASC 606. Accordingly, the Company determines revenue recognition through the following steps: • identification of the contract, or contracts, with a customer; • identification of the performance obligations in the contract; • determination of the transaction price; • allocation of the transaction price to the performance obligations in the contract; and • recognition of revenue when, or as, the Company satisfies a performance obligation. Revenues are recognized when control of these services is transferred to the Company’s customers, in an amount that reflects the consideration it expects to be entitled to in exchange for those services. The majority of the Company’s contracts with customers contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately when they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines the standalone selling prices based on our overall pricing objectives, taking into consideration market conditions, historical pricing information as priced in previous bundled contracts, as well as other factors such as product, customer type and geographic area. We typically establish a range of SSPs for each of our performance obligations. We use the residual method to the estimate the SSP for certain performance obligations with highly variable pricing. (a) Subscription and related services In most cases, the Company generates subscription fees from clients based on the number of healthcare services clients that utilize the Phreesia Platform and subscription fees for the Company’s self-service intake tablets (PhreesiaPads), on-site kiosks (Arrivals Kiosks) and any other applications. The Company’s healthcare services clients are typically billed monthly in arrears, though in some instances healthcare services clients may opt to be billed quarterly or annually in advance. Subscription fees are typically auto-debited from client’s accounts every month. Revenue for healthcare services client subscriptions is recognized over the term of the respective healthcare services client contract. The Company’s subscription arrangements are considered service contracts, and the customer does not have the right to take possession of the software. Revenue for related services is recognized as it is delivered if the services are distinct from the subscription service and is recognized over the remaining non-cancelable subscription term if it is not distinct from the subscription service. In certain arrangements, the Company leases its PhreesiaPads and Arrivals Kiosks through operating leases to its customers. Accordingly, these revenue transactions are accounted for using ASC 842, Leases . The amount of subscription and related services revenues recorded pursuant to ASC 842 for the leasing of the Company’s PhreesiaPads and Arrivals Kiosks was $10,197, $6,489 and $6,312 for the years ended January 31, 2023, 2022 and 2021, respectively. In addition, subscription and related services includes certain fees from clients for professional services associated with implementation services as well as travel and expense reimbursements, shipping and handling fees, sales of hardware (PhreesiaPads and Arrivals Kiosks), on-site support and training. Certain professional services for implementation are not distinct from Phreesia’s Platform and are therefore recognized over the term of the contract. Revenue from sales of Phreesia hardware and training are recognized in the period they are delivered to clients. (b) Payment processing fees The Company generates revenue from payment processing fees based on the levels of patient payment volume resulting from credit and debit card transactions (dollar value and number of card transactions) processed through Phreesia’s payment facilitator model. Payment processing fees are generally calculated as a percentage of the total transaction dollar value processed and/or a fee per transaction. The remainder of patient payment volume is composed of credit and debit card transactions for which Phreesia acts as a gateway to payment processors, and cash and check transactions. The Company recognizes the payment processing fees when the transaction occurs (i.e., when the processing services are completed). The transaction amount is collected from the cardholder’s bank via the Company’s third-party payment processing partner and the card networks. The transaction amount is then remitted to its customers approximately two The Company acts as the merchant of record for its customers and works with payment card networks and banks so that its customers do not need to manage the complex systems, rules, and requirements of the payment industry. The Company satisfies its performance obligations and therefore recognizes the transaction fees as revenue upon completion of a transaction. Revenue is recognized net of refunds, which arise from reversals of transactions initiated by the Company’s customers. The payment processing fees collected from customers are recognized as revenue on a gross basis as the Company is the principal in the delivery of the managed payment solutions to the customer. The Company has concluded it is the principal because as the merchant of record, it controls the services before delivery to the customer, it is primarily responsible for the delivery of the services to its customers, it has latitude in establishing pricing with respect to the customer and other terms of service, it has sole discretion in selecting the third-party to perform the settlement, and it assumes the credit risk for the transaction processed. The Company also has the unilateral ability to accept or reject a transaction based on criteria established by the Company. As the merchant of record, the Company is liable for settlement of the transactions processed and, accordingly, such costs are included in payment processing fees expense on the accompanying statements of operations. (c) Network solutions The Company's Network solutions revenue includes fees from life sciences companies and payers for direct communications to activate, engage and educate patients about topics critical to their health using the Phreesia platform. The Company generates revenue from sales of digital marketing solutions to life sciences companies which is based largely on the delivery of messages at a contracted price per message to patients. Messaging campaigns are sold for a specified number of messages delivered to qualified patients over an expected time frame. Revenue is recognized as the messages are delivered. The Company generates revenue from sales of qualified leads to health plans and other payer organizations which is based largely on the delivery of qualified leads to health plans and other payer organizations at a contracted price per lead. The Company identifies the qualified leads based on direct communications delivered to patients. Revenue for leads is recognized based on our estimate of leads accepted by health plans and other payer organizations. (d) Disaggregation of revenue Revenue from the Company’s contracts with its customers are disaggregated by service offering on the accompanying statements of operations. The Company’s core service offerings are subscription and related services, payment processing fees, digital marketing solutions sold to life sciences companies and qualified leads sold to health plans and other payer organizations. In addition, substantially all of the Company’s revenue is derived from customers in the United States. (e) Remaining performance obligations The Company does not disclose the value of unsatisfied performance obligations as the majority of its contracts relate to either contracts with an original term of one year or less or contracts with variable consideration (i.e., the Company’s payment processing fees revenue). (f) Contract balances Unbilled accounts receivable is a contract asset related to the delivery of the Company’s subscription and related services and for its life sciences revenue for which the related billings will occur in a future period. Deferred revenue is a contract liability primarily related to billings in advance of revenue recognition from the Company's subscription and life sciences services and, to a lesser extent, professional services and other revenues described above. Deferred revenue is recognized as the Company satisfies its performance obligations. The Company generally invoices its customers in monthly or quarterly installments for subscription services. Accordingly, the deferred revenue balance does not generally represent the total contract value of a subscription arrangement. Deferred revenue that will be recognized during the succeeding 12-month period is recorded as current deferred revenue on the accompanying balance sheets. Deferred revenue that will be recognized subsequent to the succeeding 12-month period is recorded as long-term deferred revenue on the accompanying balance sheets. The following table represents a roll-forward of contract assets: January 31, 2023 2022 Beginning Balance $ 392 $ 1,287 Amount transferred to receivables from beginning balance of contract assets (392) (1,287) Increases in contract assets due to acquisitions — 243 Contract asset additions, net of reclassification to receivables 989 149 Ending Balance $ 989 $ 392 The following table represents a roll-forward of deferred revenue: January 31, 2023 2022 Beginning Balance $ 16,558 $ 10,838 Revenue recognized that was included in deferred revenue at the beginning of the period (16,005) (10,838) Increases in deferred revenue due to acquisitions — 2,372 Other current year activity in deferred revenue 17,260 14,186 Ending Balance $ 17,813 $ 16,558 (g) Cost to obtain a contract The Company capitalizes certain incremental costs to obtain customer contracts and amortizes these costs over a period of benefit that the Company has estimated to be three The following table represents a roll-forward of deferred contract acquisition costs: January 31, 2023 2022 Beginning balance $ 4,079 $ 2,941 Additions to deferred contract acquisition costs 427 3,349 Amortization of deferred contract acquisition costs (1,696) (2,211) Ending balance $ 2,810 $ 4,079 Deferred contract acquisition costs, current (to be amortized in next 12 months) $ 1,056 $ 1,642 Deferred contract acquisition costs, non-current 1,754 2,437 Total deferred contract acquisition costs $ 2,810 $ 4,079

Finance leases and other debt

Finance leases and other debt	12 Months Ended
	Jan. 31, 2023
Debt Disclosure [Abstract]
Finance leases and other debt	Finance leases and other debt As of January 31, 2023 and 2022, the Company had the following outstanding finance lease liabilities and other debt: January 31, 2023 2022 Finance leases $ 7,651 $ 12,884 Financing arrangements 46 266 Accrued interest and payments 200 94 Total finance lease liabilities and other debt $ 7,897 $ 13,244 Less - current portion of finance lease liabilities and other debt (5,172) (5,821) Long-term finance leases and other debt $ 2,725 $ 7,423 (a) Finance leases See Note 10 - Leases for more information regarding finance leases. On February 28, 2019 (the "Effective Date"), the Company entered into the Amended and Restated Loan and Security Agreement (the "First SVB Facility") that provided for a $20,000 term loan. In connection with the transaction, the Company recorded a $1,073 loss on extinguishment of debt within other (expense) income, net for the settlement of previously outstanding loans payable. On May 5, 2020 (the "Second SVB Effective Date"), the Company entered into the Second SVB Facility. The Second SVB Facility modified the First SVB Facility. The Second SVB Facility provided for a revolving credit facility with an initial borrowing capacity of $50,000. The borrowing capacity could be increased to $65,000 at the sole discretion of Silicon Valley Bank. Upon entering into the Second SVB Facility, the Company borrowed $20,663 against the revolving credit facility and used the proceeds to repay all amounts due under the First SVB Facility term loan. The Company repaid the balance on the Second SVB Facility during the fiscal year ended January 31, 2021. On March 28, 2022 (the "Third SVB Effective Date"), the Company entered into a First Loan Modification Agreement to the Second SVB Facility (as amended, the "Third SVB Facility") to increase the borrowing capacity from $50,000 to $100,000 and to reduce the interest rate on the facility. Borrowings under the Third SVB Facility are payable on May 5, 2025. Borrowings under the Third SVB Facility bear interest, which is payable monthly, at a floating rate equal to the greater of 3.25% or the Wall Street Journal Prime Rate minus 0.5%. As of January 31, 2023, the interest rate on the Third SVB Facility was 7%. In addition to principal and interest due under the revolving credit facility, the Company is required to pay an annual commitment fee of approximately $250 per year and a quarterly fee of 0.15% per annum of the average unused revolving line under the facility. The Company had $100,000 of availability under the facility as of January 31, 2023. In the event that the Company terminates the Third SVB Facility prior to May 5, 2024, the Company will be required to pay a termination fee of up to 1.5% of borrowing capacity based on the length of time between termination and maturity. Any Company obligations under the Third SVB Facility are secured by a first priority security interest in substantially all of its assets, other than intellectual property. The Third SVB Facility includes a financial covenant that requires the Company to maintain a minimum Adjusted Quick Ratio as defined in the Third SVB Facility. The Third SVB Facility also includes a financial covenant that requires the Company to achieve certain profitability and liquidity thresholds. The financial covenant will not be effective if the Company maintains certain levels of liquidity as defined. Additionally, the Third SVB facility contains a covenant limiting the amount of cash and cash equivalents the Company can hold outside SVB. The Third SVB Facility also contains customary events of default. The Company was in compliance with all covenants related to the Third SVB Facility as of January 31, 2023. As of January 31, 2023 and 2022, there was no debt outstanding related to the Third SVB Facility and the Second SVB Facility, respectively. As a result, the Company presented all unamortized deferred costs within other assets as of January 31, 2023 and 2022, respectively. The Company is amortizing the remaining unamortized costs over the remaining term of the Third SVB Facility. Maturities of finance leases and other debt in each of the next five years and thereafter are as follows: Total Finance Leases Other Debt Fiscal year ending January 31: 2024 $ 5,172 $ 4,926 $ 246 2025 2,518 2,518 — 2026 207 207 — Total maturities of finance leases and other debt $ 7,897 $ 7,651 $ 246 The following table presents the components of interest income (expense), net: Fiscal years ended January 31, 2023 2022 2021 Interest expense (1) $ (1,411) $ (1,163) $ (1,695) Interest income 2,475 79 122 Interest income (expense), net $ 1,064 $ (1,084) $ (1,573) (1) Includes amortization of deferred financing costs and original issue discount

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jan. 31, 2023
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity (a) Common stock The Company closed an IPO on July 22, 2019 and filed an Amended and Restated Certificate of Incorporation authorizing the issuance of up to 500,000,000 shares of common stock, par value $0.01 per share. On April 12, 2021, the Company completed a follow-on offering of its common stock. In connection with this offering, the Company issued and sold 5,175,000 shares of common stock at an issuance price of $50.00 per share. (b) Treasury stock The Company's equity-based compensation plan allows for the grant of non-vested stock options, RSUs and TSR PSUs to its employees pursuant to the terms of its stock option and incentive plans (See Note 8). Under the provision of the plans, for RSU and PSU awards, unless otherwise elected, participants fulfill their related income tax withholding obligation by having shares withheld at the time of vesting. On the date of vesting of the RSU or PSU, the Company divides the participant's estimated income tax obligation in dollars by the closing price of its common stock and withholds the resulting number of vested shares. The shares withheld are then transferred to the Company's treasury stock at cost.

Equity-based compensation

Equity-based compensation	12 Months Ended
	Jan. 31, 2023
Share-Based Payment Arrangement [Abstract]
Equity-based compensation	Equity-based compensation (a) Equity award plans In January 2018, the Board of Directors adopted the Company’s 2018 Stock Option Plan as amended, (the "2018 Stock Option Plan") which provided for the issuance of options to purchase up to 3,048,490 shares of the Company’s common stock to officers, directors, employees, and consultants. The option exercise price per share is determined by the Board of Directors based on the estimated fair value of the Company’s common stock. In June 2019, the Board of Directors adopted the Company’s 2019 Stock Option and Incentive Plan (the "2019 Plan"), which replaced the 2018 Stock Option Plan upon the completion of the IPO. The 2019 Plan allows the Compensation Committee of the Board of Directors (the "Compensation Committee") to make equity-based incentive awards including stock options, RSUs and PSUs to the Company’s officers, employees, directors, and consultants. The initial reserve for the issuance of awards under this plan was 2,139,683 shares of common stock. The initial number of shares reserved and available for issuance automatically increased on February 1, 2020 and automatically increases each February 1 thereafter by 5% of the number of shares of common stock outstanding on the immediately preceding January 31 (or such lesser number of shares determined by the Compensation Committee). As the 2018 Stock Option Plan was replaced by the 2019 Plan, all grants of stock options, RSUs and PSUs during the years ended January 31, 2023, 2022 and 2021 were made pursuant to the 2019 plan, respectively. effectiveness of the registration statement for the Company’s initial public offering. The total shares of common stock initially reserved under the ESPP was limited to 855,873 shares. In August 2021, the Company amended its fiscal 2022 incentive bonus to allow eligible employees to elect to receive all or a portion of their fiscal 2022 year end incentive compensation in the form of immediately vested restricted stock units instead of cash. The Company's fiscal 2023 incentive bonus allows eligible employees to elect to receive all or a portion of their fiscal 2023 incentive compensation in the form of immediately vested restricted stock units instead of cash. As of January 31, 2023, there are 3,408,720 shares available for future grant pursuant to the 2019 Plan after factoring in the automatic increase which occurs on February 1 of each fiscal year, as well as an additional 576,304 shares available for future grant pursuant to the ESPP. During fiscal 2022, the Company activated its ESPP. The ESPP has two six-month offering periods each calendar year beginning in January and July. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a 15% discount through payroll deductions. (b) Summary of stock-based compensation The following table sets forth stock-based compensation by type of award: For the fiscal years ended 2023 2022 2021 RSUs $ 42,214 $ 24,222 $ 10,693 Liability awards 7,641 7,055 — PSUs 7,282 2,389 93 Stock options 1,489 2,294 2,703 ESPP 1,521 763 — Total stock-based compensation $ 60,147 $ 36,723 $ 13,489 The following table sets forth the presentation of stock-based compensation in the Company's financial statements: For the fiscal years ended 2023 2022 2021 Stock-based compensation expense recorded to additional paid-in capital (1) $ 52,506 $ 29,668 $ 13,489 Stock-based compensation expense recorded to accrued expenses 7,641 7,055 — Total stock-based compensation 60,147 36,723 13,489 Less stock-based compensation expense capitalized as internal-use software (1,372) (489) — Stock-based compensation expense per consolidated statements of operations (2) $ 58,775 $ 36,234 $ 13,489 (1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts. (2) Non-cash stock-based compensation expense included in the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations. The Company has not recognized and does not expect to recognize in the foreseeable future, any tax benefit related to employee stock-based compensation expense. (c) Restricted stock units The Company has issued restricted stock units to employees and independent directors that vest based on a time-based condition. For RSUs granted to employees prior to January 2021, pursuant to a time-based condition, 10% of the restricted stock units vest after one year, 20% vest after two years, 30% vest after three years and 40% vest after four years. The restricted stock units expire seven years from the grant date. During the year ended January 31, 2022, the Company modified the vesting of RSUs granted subsequent to January 1, 2021 for employees other than its named executive officers listed in its 2022 proxy statement ("2022 NEOs") and other members of its executive management team. Pursuant to the modified vesting schedule, RSUs granted after January 1, 2021 for employees other than 2022 NEOs and other members of its executive management team, vest 6.25% each quarter over four years based on continued service. For 2022 NEOs and other members of the Company's executive management team, RSUs granted from January 1, 2022 through December 31, 2022 vest 6.25% each quarter over four years based on continued service. Beginning January 2023, all RSUs granted vest 25% each year over four years based on continued service. Additionally, the Company provides certain employees the option to settle their incentive bonus in immediately vested RSUs. RSUs granted to settle bonus awards are included in RSUs granted and vested in the table below. See section (g) Liability awards below for additional information regarding share-settled bonus awards. Restricted stock units Unvested, January 31, 2020 1,447,418 Granted during year 972,271 Vested (242,049) Forfeited and expired (124,602) Unvested, January 31, 2021 2,053,038 Granted during year 1,836,534 Vested (559,767) Forfeited and expired (195,966) Unvested, January 31, 2022 3,133,839 Granted during year 2,907,838 Vested (1,626,679) Forfeited and expired (497,245) Unvested, January 31, 2023 3,917,753 As of January 31, 2023, there is $112,482 remaining of total unrecognized compensation costs related to these awards. The total unrecognized costs are expected to be recognized over a weighted-average term of 2.8 years. For the years ended January 31, 2023, 2022 and 2021, the weighted average grant date fair value of restricted stock units granted was $26.79, $46.60 and $32.78 respectively. (d) Stock options Options granted under the equity award plans have a maximum term of ten years and vest over a period determined by the Board of Directors (generally four years from the date of grant or the commencement of the grantee’s employment with the Company). Options generally vest 25% at the one-year anniversary of the grant date, after which point they generally vest pro rata on a monthly basis. Stock option activity for the fiscal years ended January 31, 2023, 2022 and 2021 is as follows: Number of Weighted- Weighted- Aggregate Intrinsic Outstanding—January 31, 2020 5,516,452 $ 3.80 Granted during the year — $ — Exercised (2,216,368) $ 2.39 Forfeited (88,730) $ 7.45 Outstanding and expected to vest — January 31, 2021 3,211,354 $ 4.67 5.99 $ 194,676 Outstanding—January 31, 2021 3,211,354 $ 4.67 Granted during the year — $ — Exercised (1,439,186) $ 2.88 Forfeited and expired (67,018) $ 9.02 Outstanding and expected to vest — January 31, 2022 1,705,150 $ 6.01 5.94 $ 42,938 Outstanding—January 31, 2022 1,705,150 $ 6.01 Granted during the year — $ — Exercised (311,743) $ 4.92 Forfeited and expired (8,214) $ 4.68 Outstanding and expected to vest — January 31, 2023 1,385,193 $ 6.26 5.06 $ 43,341 Exercisable — January 31, 2023 1,362,903 $ 6.12 5.03 $ 42,750 Amount vested during year ended January 31, 2023 258,735 $ 8.27 The aggregate intrinsic value represents the total pre-tax intrinsic value (the difference between the Company’s estimated stock price at the time of exercise and the exercise price, multiplied by the number of related in-the-money options) that would have been received by the option holders had they exercised their options at the end of the period. This amount changes based on the market value of the Company’s common stock. The total intrinsic value of options exercised for the years ended January 31, 2023, 2022 and 2021 (based on the difference between the Company’s estimated stock price on the exercise date and the respective exercise price, multiplied by the number of options exercised), was $6,970, $73,624 and $33,575, respectively. As of January 31, 2023, there is $45 of total unrecognized compensation cost related to stock options issued to employees that is expected to be recognized over a weighted-average term of 0.33 years. For the year ended January 31, 2023, stock-based compensation expense for stock options includes $322 related to the modification of stock options. (e) TSR performance-based restricted stock units (PSUs) The Company grants PSUs to certain members of its management team. PSUs vest over approximately three years from the grant date upon satisfaction of both time-based requirements and market targets based on Phreesia's TSR relative to the TSR of each member of the Peer Group. Depending on the percentage level at which the market-based condition is satisfied, the number of shares vesting could be between 0% and 220% of the number of PSUs originally granted. PSUs granted during the years ended January 31, 2023, 2022 and 2021 vest in a maximum of 220%, 200% and 200% of the number of PSUs originally granted, respectively. To earn the target number of PSUs (which represents 100% of the number of PSUs granted), the Company must perform at the 60th percentile, with the maximum number of PSUs earned if the Company performed at least at the 90th percentile. If Phreesia's TSR for the performance period is negative, the maximum number of PSUs that can be earned will be capped at 100%. The Company estimated the fair value of the PSUs using a Monte Carlo Simulation model which projected TSR for Phreesia and each member of the Peer Group over the performance period. The Company recognizes the grant date fair value of PSUs as compensation expense over the vesting period. The fair value of the PSUs granted during the fiscal years ended January 31, 2023, 2022 and 2021, respectively, was estimated using the following assumptions: Fiscal years ended 2023 2022 2021 Correlation coefficient 0.4957 0.3878 0.4230 Valuation date stock price $ 35.41 $ 36.03 $ 62.96 Simulation term 3.00 Years 2.99 Years 3.00 Years Volatility 64.98 % 44.32 % 43.71 % Risk-free rate 3.84 % 1.23 % 0.20 % Dividend yield — % — % — % Weighted average fair value of grants $ 56.52 $ 48.47 $ 84.38 Performance Outstanding February 1, 2020 — Granted during the year ended January 31, 2021 70,806 Outstanding, February 1, 2021 70,806 Granted during the year ended January 31, 2022 325,410 Vested — Forfeited and expired — Outstanding, February 1, 2022 396,216 Granted during the year ended January 31, 2023 255,572 Vested — Forfeited and expired (3,555) Outstanding, January 31, 2023 648,233 As of January 31, 2023, unrecognized compensation cost for the PSUs was $26,128, to be recognized over a weighted average remaining vesting period of 2.4 years, subject to the participants' continued employment with the Company. (f) Employee stock purchase plan The ESPP is a compensatory plan because it provides participants with terms that are more favorable than those offered to other holders of the Company's common stock. Employees purchase shares at the lesser of (1) 85% of the closing stock price on the first day of the offering period or (2) 85% of the closing stock price on the last day of the offering period. The ESPP is structured as a qualified employee stock purchase plan under Section 423 of the U.S. Internal Revenue Code of 1986. Year ended Year ended Risk-free interest rate 3.68 % 0.17 % Expected dividends none none Expected term (in years) 0.47 years 0.49 years Volatility 74.8 % 55.7 % within stockholders' equity. As of January 31, 2023, unrecognized compensation cost related to the ESPP was $605, to be recognized over the next five months. (g) Liability awards The Company's amended fiscal 2022 incentive bonus and the Company's fiscal 2023 incentive bonus allow eligible employees to elect to receive all or a portion of their incentive compensation in the form of immediately vested restricted stock units instead of cash. Restricted stock units issued to settle liability awards are covered by the 2019 Plan. Share-settled bonus awards will be settled at a value equal to 115% of the bonuses converted. These share-settled bonus awards vest based on the achievement of the Company’s predefined performance targets. As share-settled bonus awards will be settled in a variable number of shares, the Company classifies share-settled bonus awards as liabilities, within accrued expenses in the accompanying consolidated balance sheets until they are settled in shares and included in stockholders' equity. During the year-ended January 31, 2023, the Company settled $8,812 of share-settled bonus awards by issuing 302,931 immediately vested RSUs. See (c) Restricted Stock Units above for additional discussion regarding RSUs.

Fair value measurements

Fair value measurements	12 Months Ended
	Jan. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy (in thousands): Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2023 Money market mutual funds $ 163,563 $ — $ — $ 163,563 Total assets $ 163,563 $ — $ — $ 163,563 The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy (in thousands): Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2022 Money market mutual funds $ 197,601 $ — $ — $ 197,601 Total assets $ 197,601 $ — $ — $ 197,601 The carrying value of the Company’s short-term financial instruments, including accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. As of January 31, 2023, the carrying value of the Company's debt approximated fair value because the interest rates approximated market rates and the debt maturities were relatively short-term. The Company did not have any transfers of assets and liabilities between levels of the fair value measurements hierarchy during both the years ended January 31, 2023 and 2022.

Leases

Leases	12 Months Ended
	Jan. 31, 2023
Leases [Abstract]
Leases	Leases (a) Phreesia as Lessee The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The financial impact of the change in useful lives of the related right of use assets was not significant. Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows: January 31, 2023 2022 Operating leases: Lease right-of-use assets $ 569 $ 2,337 Lease liabilities, current 934 1,281 Lease liabilities, non-current 349 1,276 Total operating lease liabilities $ 1,283 $ 2,557 Finance leases: Property and equipment, at cost $ 27,813 $ 27,310 Accumulated depreciation (20,657) (15,025) Property and equipment, net $ 7,156 $ 12,285 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,926 5,600 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 2,725 7,284 Total finance lease liabilities $ 7,651 $ 12,884 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable. As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%. The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows: Fiscal years ended 2023 2022 2021 Operating leases: Operating lease cost $ 1,835 $ 1,096 $ 1,766 Variable lease cost 62 223 257 Total operating lease cost $ 1,897 $ 1,319 $ 2,023 Finance leases: Amortization of right-of-use assets $ 5,632 $ 4,636 $ 2,876 Interest on lease liabilities 368 378 326 Total finance lease cost $ 6,000 $ 5,014 $ 3,202 The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023: January 31, 2023 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2024 $ 958 $ 5,102 2025 225 2,566 2026 86 209 2027 42 — Thereafter 7 — Total future minimum lease payments $ 1,318 $ 7,877 Less: interest (35) (226) Present value of lease liabilities $ 1,283 $ 7,651 As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows: Fiscal years ended 2023 2022 2021 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,347 $ 1,206 $ 1,629 Operating cash used for finance leases 396 377 326 Financing cash used for finance leases 5,731 4,267 2,630 Total $ 7,474 $ 5,850 $ 4,585 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Leases	Leases (a) Phreesia as Lessee The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The financial impact of the change in useful lives of the related right of use assets was not significant. Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows: January 31, 2023 2022 Operating leases: Lease right-of-use assets $ 569 $ 2,337 Lease liabilities, current 934 1,281 Lease liabilities, non-current 349 1,276 Total operating lease liabilities $ 1,283 $ 2,557 Finance leases: Property and equipment, at cost $ 27,813 $ 27,310 Accumulated depreciation (20,657) (15,025) Property and equipment, net $ 7,156 $ 12,285 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,926 5,600 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 2,725 7,284 Total finance lease liabilities $ 7,651 $ 12,884 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable. As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%. The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows: Fiscal years ended 2023 2022 2021 Operating leases: Operating lease cost $ 1,835 $ 1,096 $ 1,766 Variable lease cost 62 223 257 Total operating lease cost $ 1,897 $ 1,319 $ 2,023 Finance leases: Amortization of right-of-use assets $ 5,632 $ 4,636 $ 2,876 Interest on lease liabilities 368 378 326 Total finance lease cost $ 6,000 $ 5,014 $ 3,202 The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023: January 31, 2023 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2024 $ 958 $ 5,102 2025 225 2,566 2026 86 209 2027 42 — Thereafter 7 — Total future minimum lease payments $ 1,318 $ 7,877 Less: interest (35) (226) Present value of lease liabilities $ 1,283 $ 7,651 As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows: Fiscal years ended 2023 2022 2021 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,347 $ 1,206 $ 1,629 Operating cash used for finance leases 396 377 326 Financing cash used for finance leases 5,731 4,267 2,630 Total $ 7,474 $ 5,850 $ 4,585 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.
Leases	Leases (a) Phreesia as Lessee The Company leases several office premises and third-party data center space in the U.S and Canada under operating leases which expire on various dates through March 2027. Certain of these arrangements have escalating rent payment provisions or optional renewal clauses. The table below only considers lease obligations through the renewal date as the Company is not reasonably certain to elect the option to extend its leases beyond the option date. No arrangements contain residual value guarantees or restrictions imposed on the leases. The Company is also committed to pay a portion of the actual operating expenses under certain of these lease agreements. These operating expenses are not included in the table below. The Company has also entered into various finance lease arrangements for computer equipment. These agreements are typically for two During the year ended January 31, 2023, the Company ceased using its office premises in Ottawa, Canada and Raleigh, North Carolina. Additionally, during the year ended January 31, 2023, the Company decided to cease using its office premise in Portland, Oregon by April 2023. In connection with these decisions, the Company shortened the useful lives of the related right of use assets to end on the cease use date for each lease. The financial impact of the change in useful lives of the related right of use assets was not significant. Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows: January 31, 2023 2022 Operating leases: Lease right-of-use assets $ 569 $ 2,337 Lease liabilities, current 934 1,281 Lease liabilities, non-current 349 1,276 Total operating lease liabilities $ 1,283 $ 2,557 Finance leases: Property and equipment, at cost $ 27,813 $ 27,310 Accumulated depreciation (20,657) (15,025) Property and equipment, net $ 7,156 $ 12,285 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,926 5,600 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 2,725 7,284 Total finance lease liabilities $ 7,651 $ 12,884 For office leases and leased equipment, the Company has elected the practical expedient to not separate lease and non-lease components, and as such, the variable lease cost primarily represents variable payments lease assets and liabilities using its incremental borrowing rate given that the implicit rate to each lease is not readily determinable. As of January 31, 2023, for operating leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.5%. As of January 31, 2023, for finance leases, the weighted-average remaining lease term is 1.6 years and the weighted-average discount rate is 3.6%. The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows: Fiscal years ended 2023 2022 2021 Operating leases: Operating lease cost $ 1,835 $ 1,096 $ 1,766 Variable lease cost 62 223 257 Total operating lease cost $ 1,897 $ 1,319 $ 2,023 Finance leases: Amortization of right-of-use assets $ 5,632 $ 4,636 $ 2,876 Interest on lease liabilities 368 378 326 Total finance lease cost $ 6,000 $ 5,014 $ 3,202 The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023: January 31, 2023 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2024 $ 958 $ 5,102 2025 225 2,566 2026 86 209 2027 42 — Thereafter 7 — Total future minimum lease payments $ 1,318 $ 7,877 Less: interest (35) (226) Present value of lease liabilities $ 1,283 $ 7,651 As of January 31, 2023, the Company has signed a finance lease for computer equipment which does not commence until April 2023. Total undiscounted payments through the fiscal year ended January 31, 2027 related to the lease are $8,058 and are excluded from the table above but are included in our other contractual commitments. See Note 11 - Commitments and contingencies for additional information regarding other contractual commitments. Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows: Fiscal years ended 2023 2022 2021 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,347 $ 1,206 $ 1,629 Operating cash used for finance leases 396 377 326 Financing cash used for finance leases 5,731 4,267 2,630 Total $ 7,474 $ 5,850 $ 4,585 (b) Phreesia as Lessor In connection with the patient intake and registration process, Phreesia offers its customers the ability to lease PhreesiaPads and Arrivals Kiosks along with their monthly subscription. These rentals fall under the guidance of ASC 842. The Company elected the practical expedient to not separate lease and non-lease components. More specifically, all contractual hardware maintenance is included with the hardware lease components. The leases contain no variable lease payments, no options to extend the lease that are reasonably certain to be exercised, and do not give the lessee an option to purchase the hardware at the end of the lease term. Additionally, the lease term does not represent a major part of the remaining economic life of the assets, and the present value of the lease payments does not equal or exceed substantially all of the fair value of the assets. As a result, all leased hardware in the SaaS arrangements are classified as operating leases. During the years ended January 31, 2023, 2022 and 2021, the Company recognized $10,197, $6,489 and $6,312, respectively in subscription and related services revenue related to the leasing of PhreesiaPads and Arrivals Kiosks.

Commitments and contingencies

Commitments and contingencies	12 Months Ended
	Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies (a) Indemnifications The Company’s agreements with certain customers include certain provisions for indemnifying customers against liabilities if its services infringe a third-party’s intellectual property rights. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances that may be involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such provisions and have not accrued a ny liabilities related to such obligations in its consolidated financial statements. In addition, the Company has indemnification agreements with its directors and its executive officers that require it, among other things, to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by any of those persons in any action or proceedi n g to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as a director or officer or that person’s services provided to any other company or enterprise at the Company’s request. The Company maintains director and officer insurance coverage that may enable it to recover a portion of any future indemnification amounts paid. To date, there have been no claims under any of its directors and executive officers indemnification provisions. (b) Legal proceedings In the ordinary course of business, the Company may be subject from time to time to various proceedings, lawsuits, disputes or claims. Although the Company cannot predict with assurance the outcome of any litigation, the Company does not believe there are currently any such actions that, if resolved unfavorably, would have a material impact on its financial condition, results of operations or cash flows. (c) Other contractual commitments Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2023 are presented in the table below. Purchase obligations Year ending January 31, 2024 $ 11,646 2025 8,115 2026 3,530 2027 598 Total $ 23,889

Income taxes

Income taxes	12 Months Ended
	Jan. 31, 2023
Income Tax Disclosure [Abstract]
Income taxes	Income taxesThe Company recorded a tax provision of $483, $182 and $49, for the years ended January 31, 2023, 2022 and 2021, respectively. The Company's provision for income taxes was 0.3%, 0.2% and 0.2% of loss before income taxes for the years ended January 31, 2023, 2022 and 2021, respectively. The Company's effective tax rate differs from the U.S. statutory tax rate of 21% primarily because the Company records a valuation allowance against the majority of its deferred tax assets, and due to foreign income tax expense recorded for the Company's Canada branch related to the use of net operating loss carry forwards to offset current income. Deferred tax assets and deferred tax liabilities are recognized based on temporary differences between the financial reporting and tax basis of assets and liabilities using statutory rates. Management of the Company has evaluated the positive and negative evidence pertaining to the realizability of its deferred tax assets, including the Company’s history of losses, and concluded that it is more likely than not that the Company will not recognize the benefits for the majority of its deferred tax assets. On the basis of this evaluation, the Company has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized at both January 31, 2023 and 2022. The Company’s loss before income taxes was primarily generated in the United States for fiscal 2023, fiscal 2022 and fiscal 2021. The Company's income tax provision consisted of the following for fiscal 2023, 2022 and 2021: Fiscal years ended January 31, 2023 2022 2021 Current tax Federal $ — $ — $ — State 49 39 114 Foreign — — — Deferred tax Federal 109 — (116) State — — (65) Foreign 325 143 116 Total provision for income taxes $ 483 $ 182 $ 49 A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2023, 2022 and 2021 is as follows: Fiscal years ended January 31, 2023 2022 2021 Federal income tax benefit at statutory rate 21 % 21 % 21 % State and local tax, net of federal benefit 5 % 9 % 10 % Permanent differences — % — % — % Equity compensation — % 6 % 44 % Foreign taxes — % — % — % Other — % — % (4) % Change in valuation allowance (26) % (36) % (71) % Effective income tax rate — % — % — % January 31, Deferred tax assets (liabilities) 2023 2022 Net operating loss carryforwards $ 131,574 $ 88,979 Stock based compensation 7,765 5,374 Accruals, reserves, and other expenses 2,763 3,697 Reserve for bad debts 530 521 Disallowed interest expense 1,934 1,934 Total deferred tax assets 144,566 100,505 Less valuation allowance (143,135) (97,279) Net deferred tax assets 1,431 3,226 Depreciation and amortization (295) (1,250) Intangible assets (305) (373) Deferred contract acquisition costs (750) (1,088) Total deferred tax liabilities (1,350) (2,711) Deferred taxes, net $ 81 $ 515 The Company has accumulated a Federal net operating loss carryforward of approximately $493,333 and $332,544 as of January 31, 2023 and 2022, respectively. This carryforward may be available to offset future income tax liabilities and will expire beginning in 2025. As of January 31, 2023, the Company's foreign branch had net operating loss carryforwards of approximately $716, which may be available to offset future income in Canada and will expire beginning in 2034. Due to the uncertainty regarding the ability to realize the benefit of the U.S. deferred tax assets primarily relating to net operating loss carryforwards, valuation allowances have been established to reduce the U.S. deferred tax assets to an amount that is more likely than not to be realized. On the basis of this evaluation, as of January 31, 2023 and 2022, the Company recorded a valuation allowance of $143,135 and $97,279, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The $45,856 increase in the valuation allowance recorded during the fiscal year ended January 31, 2023 relates primarily to deferred tax assets established and recorded during the fiscal year ended January 31, 2023. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable foreign income during the carryforward period are reduced. Under Section 382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change by value in its equity ownership over a three-year period), the corporation’s ability to use its pre-ownership change net operating loss carryforwards and other pre-ownership change tax attributes to offset its post-change income may be limited. As of January 31, 2023, the Company has U.S. net operating loss carryforwards of approximately $493.3 million. The Company has completed a Section 382 study and as a result of the analysis, it is more likely than not that the Company has experienced an “ownership change”. The Company may also experience ownership changes in the future as a result of subsequent shifts in its stock ownership. Accordingly, if the Company earns net taxable income, it is more likely than not that the Company's ability to use its pre-ownership change net operating loss carryforwards to offset U.S. federal taxable income will be subject to limitations, which could potentially result in increased future tax liability. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal, state, and foreign jurisdictions, where applicable. The Company’s tax years are still open from 2018 to present and, to the extent utilized in future years' tax returns, net operating loss carryforwards at January 31, 2023 will remain subject to examination until the respective tax year is closed. The Company records unrecognized tax benefits as liabilities or as reductions to deferred tax assets in accordance with ASC 740 and adjusts these balances when its judgement changes as a result of the evaluation of new information previously not available. The Company recognized interest and penalties related to uncertain tax positions in income tax expense. As of January 31, 2023 and for the years ended January

Net loss per share attributable

Net loss per share attributable to common stockholders	12 Months Ended
	Jan. 31, 2023
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	Net loss per share attributable to common stockholders (a) Net loss per share attributable to common stockholders Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Fiscal years ended January 31, 2023 2022 2021 Numerator: Net loss $ (176,146) $ (118,161) $ (27,292) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 52,440,067 49,888,436 39,519,640 Net loss per share attributable to common stockholders $ (3.36) $ (2.37) $ (0.69) (b) Potential dilutive securities The Company’s potential dilutive securities, which include stock options, restricted stock units, performance stock awards, and grants under the Company's ESPP, our employee stock purchase plan, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Fiscal years ended January 31, 2023 2022 2021 Stock options to purchase common stock, restricted stock units and performance stock awards 6,745,591 5,632,823 5,406,004 Employee stock purchase plan 74,685 75,370 — Total 6,820,276 5,708,193 5,406,004

Retirement savings plan

Retirement savings plan	12 Months Ended
	Jan. 31, 2023
Retirement Benefits [Abstract]
Retirement savings plan	Retirement savings planOn February 20, 2008, the Company established a retirement savings plan under Section 401(k) of the Internal Revenue Code (the “Plan”). The Plan covers substantially all U.S. full-time employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax and post-tax basis. Company contributions to the Plan may be made at the discretion of the Board of Directors of the Company. The Company did not make any contributions in the years ended January 31, 2023, 2022 or 2021

Related party transactions

Related party transactions	12 Months Ended
	Jan. 31, 2023
Related Party Transactions [Abstract]
Related party transactions	Related party transactions For the years ended January 31, 2023 and 2022, the Company recognized revenue totaling $775 and $482 for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of January 31, 2023 and 2022, accounts receivable from the pharmaceutical company totaled $339 and $173, respectively. For the years ended January 31, 2023 and 2022, the Company recognized general and administrative expenses totaling $374 and $182 for software agreements with a software company, respectively. One of the Company's independent members of its board of directors serves as the chief executive officer and on the board of directors for this software company. As of January 31, 2023 and 2022, prepaid expenses and other current assets include approximately $51 and $374 of payments to this software company, respectively. As of January 31, 2022, other assets included $51 of payments to this software company. This software company has been a related party since October 2021 when this software company's chief executive officer and board member became an independent member of the Company's board of directors, and the disclosures above represent transactions occurring while the software company was a related party. One of the Company's independent members of its board of directors has served as the chief financial officer of a software company since April 2022. The Company recognized de minimis expenses during the year ended January 31, 2023 for software agreements with this software company.

Acquisitions

Acquisitions	12 Months Ended
	Jan. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions Acquisition of Insignia Health, LLC On December 3, 2021, the Company entered into an agreement to acquire 100% of the outstanding equity of Insignia, a founder-led and mission-oriented company for cash consideration of $37,208. Insignia provides coaching and education solutions in conjunction with Insignia's exclusive worldwide license to the PAM. The PAM is a survey measuring a patient's knowledge, skills and ability to manage their care. The Company acquired Insignia to enable the Company to understand and engage patients in more personalized ways based on their level of activation. The acquisition of Insignia was accounted for as a business combination. The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid to sellers $ 37,112 Liabilities incurred to sellers 96 Total fair value of acquisition consideration $ 37,208 Cash consideration paid to sellers $ 37,112 Less: Cash acquired (2,689) Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows $ 34,423 The purchase price was allocated to the tangible assets acquired, the identifiable intangible assets acquired and the liabilities assumed based on their acquisition-date estimated fair values or other measurement bases specified by ASC 805 - Business Combinations. Cash $ 2,689 Accounts receivable 994 Prepaid expenses and other assets 358 Operating lease right-of-use assets 606 Intangibles 10,700 Goodwill 25,410 Total assets acquired 40,757 Accounts payable (84) Accrued liabilities (487) Deferred revenue (2,372) Operating lease liabilities (606) Total purchase price $ 37,208 The components of intangible assets acquired were as follows: Estimated Useful Life Fair Value PAM license 15 $ 6,200 Customer relationships 10 4,500 Total identifiable intangible assets acquired $ 10,700 The weighted average amortization period for acquired intangible assets as of the date of acquisition is 13 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets of Insignia. The fair value of the acquired PAM license was estimated using the relief from royalty method. The fair value of customer relationships was estimated using a multi period excess earnings method. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with each asset. The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not expected to be deductible for income tax purposes. The goodwill recognized in the acquisition of Insignia is primarily attributable to expected synergies of the combined businesses driven by integrating the PAM into the Phreesia Platform and engaging with patients in more personalized ways based on their level of activation, as well as the acquisition of an assembled workforce. The goodwill is expected to be deductible for tax purposes. On January 8, 2021, the Company entered into a stock purchase agreement with QueueDr to acquire 100% of the outstanding equity of QueueDr, an early-stage software company that automates the process of rescheduling cancellations and no-shows. We acquired QueueDr to enhance our appointments solution. The acquisition of QueueDr was accounted for as a business combination. The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid on acquisition date $ 5,773 Liabilities incurred 2,111 Contingent consideration 2,240 Total fair value of acquisition consideration $ 10,124 The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021: Cash consideration paid on acquisition date $ 5,773 Payments of acquisition date fair value of contingent consideration 954 Less cash acquired (217) Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows $ 6,510 During the fiscal year ended January 31, 2021, the Company incurred $282 of acquisition related costs for the acquisition of QueueDr. During the fiscal year ended January 31, 2022, the Company incurred $258 of expenses to remeasure the acquisition-date fair value of contingent consideration to its ultimate settlement amount of $1,544. Each of these costs were included within general and administrative expenses in our consolidated statements of operations. During the years ended January 31, 2023 and, 2022, the Company recorded certain measurement period adjustments related to the acquisitions of Insignia and QueueDr. The financial impact of measurement period adjustments was not material.

Subsequent event

Subsequent event	12 Months Ended
	Jan. 31, 2023
Subsequent Events [Abstract]
Subsequent event	Subsequent event On March 10, 2023, Silicon Valley Bank ("SVB") was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation ("FDIC") as receiver. On March 9, 2023, the Company transferred a substantial portion of its cash and cash equivalents from SVB to other financial institutions. The Company had total cash and cash equivalents of approximately $170 million as of March 10, 2023. On March 12, 2023, a Joint Statement by the U.S. Treasury, Federal Reserve, and FDIC, and a statement by the Federal Reserve Board, was issued stating that actions were approved enabling the FDIC to complete its resolutions of SVB in a manner that fully protects all depositors. As a result of actions taken by the Company to move a substantial portion of its cash to other financial institutions and the actions taken by the FDIC on March 12, 2023, the Company has determined that all of its cash and cash equivalents continue to be available for use by the Company. The Company is also party to the Third SVB Facility which contains certain restrictive covenants including a covenant that limits the Company's ability to retain specified levels of cash in accounts outside of SVB. On March 10, 2023, in connection with the transfer of a substantial portion of the Company’s cash and cash equivalents from SVB to other financial institutions, the Company obtained consent from SVB to hold up to $165 million of cash in accounts outside SVB until May 15, 2023. The consent serves to permit the Company to borrow against the Third SVB Facility once the cash and cash equivalents retained outside of SVB are compliant with the covenant and so long as the company remains in compliance with all other covenants under the Third SVB Facility. With the exception of this consent, the SVB developments and related FDIC actions noted above have not materially impacted the Company's financial position or its operations.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	12 Months Ended
	Jan. 31, 2023
Accounting Policies [Abstract]
Consolidated Financial Statements	Consolidated Financial StatementsThe accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and regulations of the Securities and Exchange Commission ("SEC") regarding annual financial reporting and include the accounts of Phreesia, Inc; its branch operation in Canada and its consolidated subsidiaries (collectively, the "Company").
Fiscal year	Fiscal yearThe Company’s fiscal year ends on January 31. References to fiscal 2023, 2022 and 2021 refer to the fiscal years ended January 31, 2023, 2022 and 2021, respectively.
Use of estimates	Use of estimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant assumptions and estimates relate to the allowance for doubtful accounts, capitalized internal-use software, the determination of the useful lives of property and equipment, the fair value of securities underlying stock-based compensation, the fair value of identifiable assets and liabilities and contingent consideration in business acquisitions, and the realization of deferred tax assets.
Revenue recognition	Revenue recognition The Company evaluates its contractual arrangements to determine the performance obligations and transaction prices. Revenue is allocated to each performance obligation and recognized when the related performance obligations are satisfied. See Note 5 for additional information regarding ASC 606, Revenue from Contracts with Customers , as well as for additional details about the Company's products and service lines.
Concentrations of credit risk and risks and uncertainties	Concentrations of credit riskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable and settlement assets. The Company’s cash and cash equivalents are held by established financial institutions. The Company does not require collateral from its customers and generally requires payment within 30 to 60 days of billing. Settlement assets are amounts due from well-established payment processing companies and normally take one two
Cost of revenue (excluding depreciation and amortization)	Cost of revenue (excluding depreciation and amortization)Cost of revenue (excluding depreciation and amortization) primarily consists of personnel expenses for implementation and technical support, costs to verify insurance eligibility and benefits, infrastructure costs for operation of our SaaS-based Phreesia Platform such as hosting fees and certain fees paid to various third-party providers for the use of their technology. Personnel expenses consist of salaries, benefits, bonuses and stock-based compensation.
Payment processing expense	Payment processing expensePayment processing expense consists primarily of interchange fees set by payment card networks that are ultimately paid to the card-issuing financial institution, and assessment fees paid to payment card networks that are ultimately paid to third-party payment processors and gateways.
Sales and marketing	Sales and marketingSales and marketing expense consists primarily of personnel costs, including salaries, benefits, bonuses, stock-based compensation and commission costs for our sales and marketing personnel. Sales and marketing expense also include costs for advertising, promotional and other marketing activities, as well as certain fees paid to various third-party partners for sales lead generation. Advertising is expensed as incurred.
Research and development	Research and developmentResearch and development expense consists of costs for the design, development, testing and enhancement of the Company’s products and services and are generally expensed as incurred. These costs consist primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our development personnel. Research and development expense also includes product management, life sciences analytics costs, third-party partner fees and third-party consulting fees, offset by any internal-use software development cost capitalized during the same period.
General and administrative	General and administrativeGeneral and administrative expense consists primarily of personnel costs, including salaries, benefits, bonuses, and stock-based compensation for our executive, finance, legal, human resources, information technology, and other administrative personnel. General and administrative expense also includes consulting, legal, security, accounting services and allocated overhead.
Depreciation and amortization	DepreciationDepreciation represents depreciation expense for PhreesiaPads and Arrivals Kiosks (collectively, Phreesia hardware), data center and other computer hardware, purchased computer software, furniture and fixtures and leasehold improvements.AmortizationAmortization primarily represents amortization of our capitalized internal-use software related to the Phreesia Platform as well as amortization of acquired intangible assets.
Cash and cash equivalents	Cash and cash equivalentsThe Company considers all highly liquid investments with an original maturity of three months or less at the time of purchase to be cash equivalents. The Company's money market accounts meet the definition of cash equivalents.
Settlement assets	Settlement assets Settlement assets represent amounts due from the Company’s payment processor for customer electronic processing transactions. Settlement assets are typically settled within one two
Settlement obligations	Settlement obligationsSettlement obligations represent amounts due to customers for electronic processing transactions that have not been funded by the Company due to timing of settlement from the Company’s payment processor.
Accounts receivable	Accounts receivableAccounts receivable represent trade receivables, net of allowances for doubtful accounts. The Company estimates the allowance for doubtful accounts as its current estimate of expected credit loss over the life of the instrument. The Company determines the allowance based on historical trends of accounts receivable balances that have been written off and specific account analysis of at-risk customers, the length of time accounts are past due, a customer's current ability to pay its obligations to the Company, the condition of the industry as a whole, as well as expected future changes in credit losses. Accounts receivable are written off at the point that internal collections efforts have been exhausted.
Property and equipment	Property and equipment Property and equipment, including PhreesiaPads and Arrivals Kiosks, are stated at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the related assets. The estimated useful lives of the Company’s property and equipment have been estimated to be between three Upon sale or disposition of property and equipment, the cost and related accumulated depreciation are removed from their respective accounts and any gain or loss is reflected in the statements of operations.
Capitalized internal-use software	Capitalized internal-use software The Company capitalizes certain costs incurred for the development of computer software for internal use pursuant to ASC 350-40, Intangibles—Goodwill and Other—Internal use software . These costs relate to the development of its Phreesia Platform. The Company capitalizes the costs during the development of the project, when it is determined that it is probable that the project will be completed, and the software will be used as intended. Costs related to preliminary project activities, post-implementation activities, training and maintenance are expensed as incurred. Internal-use software is amortized on a straight-line basis over its estimated useful life, which is generally three
Business combinations	Business combinationsThe Company uses its best estimates and assumptions to accurately assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. The Company’s estimates are inherently uncertain and subject to refinement. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the fair value of these tangible and intangible assets acquired and liabilities assumed, with the corresponding offset to goodwill. The Company continues to collect information and reevaluate these estimates and assumptions quarterly and records any adjustments to its preliminary estimates to goodwill provided that the Company is within the measurement period. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the consolidated statement of operations. When applicable, the consideration transferred for business combinations includes the acquisition-date fair value of contingent consideration. Changes in the fair value of contingent consideration liabilities are included in general and administrative expense in the accompanying consolidated statements of operations.
Goodwill and intangible assets	Goodwill and intangible assets Goodwill represents the excess of the consideration transferred over the fair value of the underlying net tangible and intangible assets acquired and liabilities assumed in connection with business combinations accounted for using the acquisition method of accounting. Goodwill is not amortized, but instead goodwill is required to be tested for impairment annually and under certain circumstances. We perform such testing of goodwill in the fourth quarter of each fiscal year, or as events occur or circumstances change that would more likely than not reduce the fair value below its carrying amount. The testing of goodwill is performed at the reporting unit level. The Company’s reporting unit is the same as its operating segment. The test begins with a qualitative assessment to determine whether it is “more likely than not” that the fair value of the reporting unit is less than its carrying amount. If it is concluded that it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative goodwill impairment test by calculating the fair value of the reporting unit and comparing that fair value to the carrying value of the reporting unit. If the estimated fair value of the reporting unit is less than its carrying amount, the Company records a goodwill impairment to reduce the carrying amount of goodwill by the amount by which the fair value of the reporting unit is less than its carrying amount. All other intangible assets associated with purchased intangibles, consisting of customer relationships, acquired technology and acquired licenses, are stated at cost less accumulated amortization and are amortized on a straight-line basis over their estimated remaining economic lives.
Long-lived assets	Long-lived assetsLong-lived assets, such as property and equipment, intangible assets, capitalized internal-use software and operating lease right-of-use assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares the undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. There were no impairment charges recognized during any of the periods presented.
Income taxes	Income taxes An asset and liability approach is used for financial accounting and reporting of current and deferred income taxes. Deferred income tax assets and liabilities are computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future. Such deferred income tax asset and liability computations are based on enacted tax laws and rates applicable to periods in which the differences are expected to affect taxable income or loss. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company follows the guidance in ASC 740, Accounting for Uncertainty in Income Taxes . ASC 740 clarifies the accounting for uncertainty in income taxes recognized in a Company’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in the interim periods, and disclosure. The Company reviews and evaluates tax positions in its major jurisdictions and determines whether or not there are uncertain tax positions that require financial statement recognition and the recording of a tax liability or the reduction of a tax asset. The Company would recognize tax related interest and penalties, if applicable, as a component of its provision for income taxes.
Segment information	Segment informationOperating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Company defines the term “chief operating decision maker” to be its Chief Executive Officer. The Company’s Chief Executive Officer reviews the financial information presented on an entire company basis for purposes of allocating resources and evaluating our financial performance. Accordingly, we have determined that we operate in a single reportable operating segment. Additionally, substantially all of the Company's revenues and long-lived assets are located in the U.S. Since the Company operates in one operating segment and substantially all of the Company's revenues and long-lived assets are located in the U.S., all required financial segment information can be found in the consolidated financial statements.
Stock-based compensation	Stock-based compensation The Company has stock-based compensation plans under which various types of equity-based awards are granted, including stock options, restricted stock units ("RSUs"), performance-based RSUs, and market-based performance stock units ("PSUs"). The compensation for the stock-based awards is recognized in accordance with ASC 718 , Compensation — Stock Compensation , which requires that compensation cost be recognized for awards based on the grant-date fair value of the award. That cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the award. For performance-based RSUs, the number of shares expected to vest is estimated at each reporting date based on management's expectations regarding the relevant performance criteria.
Fair value of financial instruments	Fair value of financial instruments Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are required to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market. Level 3—Unobservable inputs which are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
Equity offering costs	Equity offering costsThe Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering, to the extent there are sufficient proceeds. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the consolidated statement of operations.
Foreign currency	Foreign currencyThe Company has a branch office in Canada that provides operational support. The functional currency of the Company’s foreign branch is the U.S. dollar. Accordingly, assets and liabilities of the Company’s foreign branch are re-measured into U.S. dollars at the exchange rates in effect at the reporting date with differences recorded as transaction gains and losses within other (expense) income, net.
New accounting pronouncements	New accounting pronouncements Impact of recently adopted accounting pronouncements During the year ended January 31, 2023, the Company did not adopt any accounting pronouncements. Recent accounting pronouncements not yet adopted There are no recently issued accounting pronouncements the Company has not yet adopted that will materially impact the Company's consolidated financial statements.

Composition of certain financ_2

Composition of certain financial statement captions (Tables)	12 Months Ended
	Jan. 31, 2023
Composition Of Certain Financial Statement [Abstract]
Schedule of accrued expenses	Accrued expenses at January 31, 2023 and 2022 are as follows: January 31, 2023 2022 Payroll-related expenses and taxes $ 10,345 $ 10,780 Payment processing fees liability 4,796 3,502 Acquisition-related liabilities 96 96 Tax liabilities 1,491 2,093 Information technology services 2,249 1,266 Other 2,833 2,391 Total $ 21,810 $ 20,128
Schedule of property and equipment	Property and equipment at January 31, 2023 and 2022 are as follows: Useful life January 31, 2023 2022 PhreesiaPads and Arrivals Kiosks 3 $ 17,932 $ 26,387 Computer equipment 3 54,485 53,957 Computer software 3 to 5 8,571 5,311 Hardware development 3 529 1,024 Furniture and fixtures 7 — 539 Leasehold improvements 2 — 748 Total property and equipment $ 81,517 $ 87,966 Less accumulated depreciation (59,847) (53,321) Property and equipment — net $ 21,670 $ 34,645
Schedule of intangible assets	The following presents the details of intangible assets as of January 31, 2023 and January 31, 2022. Useful Life January 31, (years) 2023 2022 Acquired technology 5 $ 1,410 $ 1,410 Customer relationship 7 to 10 6,340 6,340 License 15 6,200 6,200 Total intangible assets, gross carrying value $ 13,950 $ 13,950 Less accumulated amortization (2,549) (1,178) Net carrying value $ 11,401 $ 12,772
Schedule of estimated amortization expense for intangible assets	The estimated amortization expense for intangible assets for the next five years and thereafter is as follows as of January 31, 2023: January 31, 2023 2024 $ 1,358 2025 1,273 2026 1,242 2027 949 Thereafter 6,579 Total $ 11,401
Schedule of goodwill	The following table presents a roll-forward of goodwill for the years ended January 31, 2022 and 2023: Balance at January 31, 2021 $ 8,307 Goodwill acquired during the year ended January 31, 2022 25,314 Balance at January 31, 2022 33,621 Measurement period adjustments to goodwill during the year ended January 31, 2023 115 Balance at January 31, 2023 $ 33,736
Schedule of accounts receivable	Accounts Receivable as of January 31, 2023 and 2022 are as follows: January 31, 2023 2022 Billed $ 51,458 $ 40,733 Unbilled 989 392 Total accounts receivable, gross 52,447 41,125 Less accounts receivable allowances (1,053) (863) Total accounts receivable $ 51,394 $ 40,262
Schedule of allowance for doubtful accounts	Activity in our allowance for doubtful accounts was as follows for the years ended January 31, 2023 and 2022: Balance, January 31, 2021 $ 699 Bad debt expense 212 Write-offs and adjustments (48) Balance, January 31, 2022 863 Bad debt expense 587 Write-offs and adjustments (397) Balance, January 31, 2023 $ 1,053
Schedule of prepaid and other current assets	Prepaid and other current assets as of January 31, 2023 and 2022 are as follows: January 31, 2023 2022 Prepaid software and business systems $ 3,426 $ 3,738 Prepaid data center expenses 2,389 3,230 Prepaid insurance 1,552 1,924 Other prepaid expenses and other current assets 3,342 2,151 Total prepaid and other current assets $ 10,709 $ 11,043

Revenue and Contract Costs (Tab

Revenue and Contract Costs (Tables)	12 Months Ended
	Jan. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of rollforward of contract assets and contract liabilities	The following table represents a roll-forward of contract assets: January 31, 2023 2022 Beginning Balance $ 392 $ 1,287 Amount transferred to receivables from beginning balance of contract assets (392) (1,287) Increases in contract assets due to acquisitions — 243 Contract asset additions, net of reclassification to receivables 989 149 Ending Balance $ 989 $ 392 The following table represents a roll-forward of deferred revenue: January 31, 2023 2022 Beginning Balance $ 16,558 $ 10,838 Revenue recognized that was included in deferred revenue at the beginning of the period (16,005) (10,838) Increases in deferred revenue due to acquisitions — 2,372 Other current year activity in deferred revenue 17,260 14,186 Ending Balance $ 17,813 $ 16,558
Schedule of deferred contract acquisition costs	The following table represents a roll-forward of deferred contract acquisition costs: January 31, 2023 2022 Beginning balance $ 4,079 $ 2,941 Additions to deferred contract acquisition costs 427 3,349 Amortization of deferred contract acquisition costs (1,696) (2,211) Ending balance $ 2,810 $ 4,079 Deferred contract acquisition costs, current (to be amortized in next 12 months) $ 1,056 $ 1,642 Deferred contract acquisition costs, non-current 1,754 2,437 Total deferred contract acquisition costs $ 2,810 $ 4,079

Finance leases and other debt (

Finance leases and other debt (Tables)	12 Months Ended
	Jan. 31, 2023
Debt Disclosure [Abstract]
Schedule of long-term debt instruments	As of January 31, 2023 and 2022, the Company had the following outstanding finance lease liabilities and other debt: January 31, 2023 2022 Finance leases $ 7,651 $ 12,884 Financing arrangements 46 266 Accrued interest and payments 200 94 Total finance lease liabilities and other debt $ 7,897 $ 13,244 Less - current portion of finance lease liabilities and other debt (5,172) (5,821) Long-term finance leases and other debt $ 2,725 $ 7,423
Schedule of long-term debt and finance lease maturities	Maturities of finance leases and other debt in each of the next five years and thereafter are as follows: Total Finance Leases Other Debt Fiscal year ending January 31: 2024 $ 5,172 $ 4,926 $ 246 2025 2,518 2,518 — 2026 207 207 — Total maturities of finance leases and other debt $ 7,897 $ 7,651 $ 246
Schedule of components of interest income (expense)	The following table presents the components of interest income (expense), net: Fiscal years ended January 31, 2023 2022 2021 Interest expense (1) $ (1,411) $ (1,163) $ (1,695) Interest income 2,475 79 122 Interest income (expense), net $ 1,064 $ (1,084) $ (1,573) (1) Includes amortization of deferred financing costs and original issue discount

Equity-based compensation (Tabl

Equity-based compensation (Tables)	12 Months Ended
	Jan. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of stock based compensation by type of award	The following table sets forth stock-based compensation by type of award: For the fiscal years ended 2023 2022 2021 RSUs $ 42,214 $ 24,222 $ 10,693 Liability awards 7,641 7,055 — PSUs 7,282 2,389 93 Stock options 1,489 2,294 2,703 ESPP 1,521 763 — Total stock-based compensation $ 60,147 $ 36,723 $ 13,489
Schedule of stock based compensation in financial statements	The following table sets forth the presentation of stock-based compensation in the Company's financial statements: For the fiscal years ended 2023 2022 2021 Stock-based compensation expense recorded to additional paid-in capital (1) $ 52,506 $ 29,668 $ 13,489 Stock-based compensation expense recorded to accrued expenses 7,641 7,055 — Total stock-based compensation 60,147 36,723 13,489 Less stock-based compensation expense capitalized as internal-use software (1,372) (489) — Stock-based compensation expense per consolidated statements of operations (2) $ 58,775 $ 36,234 $ 13,489 (1) Stock-based compensation included in the Company's consolidated statements of stockholders' equity is consistent with these amounts. (2) Non-cash stock-based compensation expense included in the Company's consolidated statement of cash flows for the fiscal year ended January 31, 2022 was $36,144, and excluded $90 of cash-settled stock-based compensation expense included in the Company's statements of operations.
Schedule of restricted stock unit activity	Restricted stock units Unvested, January 31, 2020 1,447,418 Granted during year 972,271 Vested (242,049) Forfeited and expired (124,602) Unvested, January 31, 2021 2,053,038 Granted during year 1,836,534 Vested (559,767) Forfeited and expired (195,966) Unvested, January 31, 2022 3,133,839 Granted during year 2,907,838 Vested (1,626,679) Forfeited and expired (497,245) Unvested, January 31, 2023 3,917,753
Schedule of stock option activity	Stock option activity for the fiscal years ended January 31, 2023, 2022 and 2021 is as follows: Number of Weighted- Weighted- Aggregate Intrinsic Outstanding—January 31, 2020 5,516,452 $ 3.80 Granted during the year — $ — Exercised (2,216,368) $ 2.39 Forfeited (88,730) $ 7.45 Outstanding and expected to vest — January 31, 2021 3,211,354 $ 4.67 5.99 $ 194,676 Outstanding—January 31, 2021 3,211,354 $ 4.67 Granted during the year — $ — Exercised (1,439,186) $ 2.88 Forfeited and expired (67,018) $ 9.02 Outstanding and expected to vest — January 31, 2022 1,705,150 $ 6.01 5.94 $ 42,938 Outstanding—January 31, 2022 1,705,150 $ 6.01 Granted during the year — $ — Exercised (311,743) $ 4.92 Forfeited and expired (8,214) $ 4.68 Outstanding and expected to vest — January 31, 2023 1,385,193 $ 6.26 5.06 $ 43,341 Exercisable — January 31, 2023 1,362,903 $ 6.12 5.03 $ 42,750 Amount vested during year ended January 31, 2023 258,735 $ 8.27
Schedule of measurement inputs and valuation techniques	The fair value of the PSUs granted during the fiscal years ended January 31, 2023, 2022 and 2021, respectively, was estimated using the following assumptions: Fiscal years ended 2023 2022 2021 Correlation coefficient 0.4957 0.3878 0.4230 Valuation date stock price $ 35.41 $ 36.03 $ 62.96 Simulation term 3.00 Years 2.99 Years 3.00 Years Volatility 64.98 % 44.32 % 43.71 % Risk-free rate 3.84 % 1.23 % 0.20 % Dividend yield — % — % — % Weighted average fair value of grants $ 56.52 $ 48.47 $ 84.38
Schedule of market-based performance stock unit activity	Market based PSU activity for the years ended January 31, 2023, 2022 and 2021 are as follows: Performance Outstanding February 1, 2020 — Granted during the year ended January 31, 2021 70,806 Outstanding, February 1, 2021 70,806 Granted during the year ended January 31, 2022 325,410 Vested — Forfeited and expired — Outstanding, February 1, 2022 396,216 Granted during the year ended January 31, 2023 255,572 Vested — Forfeited and expired (3,555) Outstanding, January 31, 2023 648,233
Schedule of ESPP valuation assumptions	The fair value of shares granted under the ESPP during the year ended January 31, 2023 was estimated using a Black-Scholes pricing model with the following assumptions: Year ended Year ended Risk-free interest rate 3.68 % 0.17 % Expected dividends none none Expected term (in years) 0.47 years 0.49 years Volatility 74.8 % 55.7 %

Fair value measurements (Tables

Fair value measurements (Tables)	12 Months Ended
	Jan. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of fair value, assets and liabilities measured on recurring basis	The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2023 and indicates the classification of each item within the fair value hierarchy (in thousands): Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2023 Money market mutual funds $ 163,563 $ — $ — $ 163,563 Total assets $ 163,563 $ — $ — $ 163,563 The following table presents information about the Company's assets and liabilities that are measured at fair value as of January 31, 2022 and indicates the classification of each item within the fair value hierarchy (in thousands): Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Balance as of January 31, 2022 Money market mutual funds $ 197,601 $ — $ — $ 197,601 Total assets $ 197,601 $ — $ — $ 197,601

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jan. 31, 2023
Leases [Abstract]
Schedule of operating and finance leases	Supplemental balance sheet information related to operating and finance leases as of January 31, 2023 and 2022 was as follows: January 31, 2023 2022 Operating leases: Lease right-of-use assets $ 569 $ 2,337 Lease liabilities, current 934 1,281 Lease liabilities, non-current 349 1,276 Total operating lease liabilities $ 1,283 $ 2,557 Finance leases: Property and equipment, at cost $ 27,813 $ 27,310 Accumulated depreciation (20,657) (15,025) Property and equipment, net $ 7,156 $ 12,285 Lease liabilities, current (included in Current portion of finance lease liabilities and other debt) 4,926 5,600 Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt) 2,725 7,284 Total finance lease liabilities $ 7,651 $ 12,884
Schedule of lease expense and cash flow information	The components of lease expense for the years ended January 31, 2023, 2022 and 2021 were as follows: Fiscal years ended 2023 2022 2021 Operating leases: Operating lease cost $ 1,835 $ 1,096 $ 1,766 Variable lease cost 62 223 257 Total operating lease cost $ 1,897 $ 1,319 $ 2,023 Finance leases: Amortization of right-of-use assets $ 5,632 $ 4,636 $ 2,876 Interest on lease liabilities 368 378 326 Total finance lease cost $ 6,000 $ 5,014 $ 3,202 Other supplemental cash flow information for the years ended January 31, 2023, 2022 and 2021 was as follows: Fiscal years ended 2023 2022 2021 Supplemental cash flow information Cash paid for amounts included in the measurement of lease liabilities: Operating cash used for operating leases $ 1,347 $ 1,206 $ 1,629 Operating cash used for finance leases 396 377 326 Financing cash used for finance leases 5,731 4,267 2,630 Total $ 7,474 $ 5,850 $ 4,585
Schedule of maturing lease commitments of operating leases	The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023: January 31, 2023 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2024 $ 958 $ 5,102 2025 225 2,566 2026 86 209 2027 42 — Thereafter 7 — Total future minimum lease payments $ 1,318 $ 7,877 Less: interest (35) (226) Present value of lease liabilities $ 1,283 $ 7,651
Schedule of maturing lease commitments of finance leases	The following represents a schedule of maturing lease commitments for operating and finance leases as of January 31, 2023: January 31, 2023 Operating Finance Maturity of lease liabilities Fiscal year ending January 31, 2024 $ 958 $ 5,102 2025 225 2,566 2026 86 209 2027 42 — Thereafter 7 — Total future minimum lease payments $ 1,318 $ 7,877 Less: interest (35) (226) Present value of lease liabilities $ 1,283 $ 7,651

Commitment and contingencies (T

Commitment and contingencies (Tables)	12 Months Ended
	Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Minimum Payments Under Purchase Commitments	Other contractual commitments consist primarily of non-cancelable purchase commitments to support our technology infrastructure. Future minimum payments under our non-cancelable purchase commitments as of January 31, 2023 are presented in the table below. Purchase obligations Year ending January 31, 2024 $ 11,646 2025 8,115 2026 3,530 2027 598 Total $ 23,889

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Jan. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of income tax (benefit)	The Company's income tax provision consisted of the following for fiscal 2023, 2022 and 2021: Fiscal years ended January 31, 2023 2022 2021 Current tax Federal $ — $ — $ — State 49 39 114 Foreign — — — Deferred tax Federal 109 — (116) State — — (65) Foreign 325 143 116 Total provision for income taxes $ 483 $ 182 $ 49
Schedule of effective tax rate	A reconciliation of the statutory U.S. federal income tax rate to the Company's effective tax rate for the years ended January 31, 2023, 2022 and 2021 is as follows: Fiscal years ended January 31, 2023 2022 2021 Federal income tax benefit at statutory rate 21 % 21 % 21 % State and local tax, net of federal benefit 5 % 9 % 10 % Permanent differences — % — % — % Equity compensation — % 6 % 44 % Foreign taxes — % — % — % Other — % — % (4) % Change in valuation allowance (26) % (36) % (71) % Effective income tax rate — % — % — %
Schedule of deferred tax assets and liabilities	January 31, Deferred tax assets (liabilities) 2023 2022 Net operating loss carryforwards $ 131,574 $ 88,979 Stock based compensation 7,765 5,374 Accruals, reserves, and other expenses 2,763 3,697 Reserve for bad debts 530 521 Disallowed interest expense 1,934 1,934 Total deferred tax assets 144,566 100,505 Less valuation allowance (143,135) (97,279) Net deferred tax assets 1,431 3,226 Depreciation and amortization (295) (1,250) Intangible assets (305) (373) Deferred contract acquisition costs (750) (1,088) Total deferred tax liabilities (1,350) (2,711) Deferred taxes, net $ 81 $ 515

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	12 Months Ended
	Jan. 31, 2023
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Fiscal years ended January 31, 2023 2022 2021 Numerator: Net loss $ (176,146) $ (118,161) $ (27,292) Denominator: Weighted-average shares of common stock outstanding, basic and diluted 52,440,067 49,888,436 39,519,640 Net loss per share attributable to common stockholders $ (3.36) $ (2.37) $ (0.69)
Schedule of shares excluded from computation of diluted net loss per share	The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Fiscal years ended January 31, 2023 2022 2021 Stock options to purchase common stock, restricted stock units and performance stock awards 6,745,591 5,632,823 5,406,004 Employee stock purchase plan 74,685 75,370 — Total 6,820,276 5,708,193 5,406,004

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jan. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of purchase price considerations at acquisition date	The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid to sellers $ 37,112 Liabilities incurred to sellers 96 Total fair value of acquisition consideration $ 37,208 Cash consideration paid to sellers $ 37,112 Less: Cash acquired (2,689) Cash paid for acquisition of Insignia, net of cash acquired per statement of cash flows $ 34,423 The following table summarizes the purchase price consideration based on the estimated acquisition-date fair value of the acquisition consideration: Cash consideration paid on acquisition date $ 5,773 Liabilities incurred 2,111 Contingent consideration 2,240 Total fair value of acquisition consideration $ 10,124 The following table summarizes the calculation of cash paid for the acquisition of QueueDr, net of cash acquired per the Company's consolidated statement of cash flows for the year ended January 31, 2021: Cash consideration paid on acquisition date $ 5,773 Payments of acquisition date fair value of contingent consideration 954 Less cash acquired (217) Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows $ 6,510
Schedule of allocation of purchase price of assets acquired and liabilities assumed	The following table summarizes the final allocation of the purchase price to the assets acquired and liabilities assumed at the date of acquisition: Cash $ 2,689 Accounts receivable 994 Prepaid expenses and other assets 358 Operating lease right-of-use assets 606 Intangibles 10,700 Goodwill 25,410 Total assets acquired 40,757 Accounts payable (84) Accrued liabilities (487) Deferred revenue (2,372) Operating lease liabilities (606) Total purchase price $ 37,208
Schedule of intangible assets acquired	The components of intangible assets acquired were as follows: Estimated Useful Life Fair Value PAM license 15 $ 6,200 Customer relationships 10 4,500 Total identifiable intangible assets acquired $ 10,700

Background and liquidity (Detai

Background and liquidity (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Mar. 10, 2023	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Debt Instrument [Line Items]
Cash and cash equivalents	$ 176,683		$ 313,812	$ 218,781	$ 90,315
Third SVB Facility
Debt Instrument [Line Items]
Number of months with sufficient funds to operate (in months)	12 months
Third SVB Facility | Subsequent event
Debt Instrument [Line Items]
Cash and cash equivalents		$ 170,000
Third SVB Facility | Revolving credit facility | Subsequent event
Debt Instrument [Line Items]
Allowable cash hold outside of facility		$ 165,000

Summary of significant accoun_3

Summary of significant accounting policies (Details)	12 Months Ended
	Jan. 31, 2023 USD ($) segment processor	Jan. 31, 2022 USD ($)	Jan. 31, 2021 USD ($)
Accounting Policies [Line Items]
Settlement period (in days)	2 days
Number of third party payment processors | processor	1
Advertising expense	$ 2,634,000	$ 4,007,000	$ 558,000
Allowance for doubtful accounts	1,053,000	863,000	699,000
Asset impairment charges	$ 0	$ 0	$ 0
Number of operating segment | segment	1
ESPP
Accounting Policies [Line Items]
Employee purchase price of common stock (as a percent)	85%
Customer One | Revenue Benchmark | Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk (as a percent)	10%	10%
Minimum
Accounting Policies [Line Items]
Customer payment period	30 days
Settlement period (in days)	1 day
Useful life (in years)	3 years
Minimum | Computer software
Accounting Policies [Line Items]
Estimated useful life (in years)	3 years
Maximum
Accounting Policies [Line Items]
Customer payment period	60 days
Settlement period (in days)	2 days
Useful life (in years)	7 years
Maximum | Computer software
Accounting Policies [Line Items]
Estimated useful life (in years)	5 years

Composition of certain financ_3

Composition of certain financial statement captions - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]
Payroll-related expenses and taxes	$ 10,345	$ 10,780
Payment processing fees liability	4,796	3,502
Acquisition-related liabilities	96	96
Tax liabilities	1,491	2,093
Information technology services	2,249	1,266
Other	2,833	2,391
Total	$ 21,810	$ 20,128

Composition of certain financ_4

Composition of certain financial statement captions - Schedule of property and equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 81,517	$ 87,966
Less accumulated depreciation	(59,847)	(53,321)
Property and equipment — net	$ 21,670	34,645
Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	7 years
PhreesiaPads and Arrivals Kiosks
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 17,932	26,387
Computer equipment
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 54,485	53,957
Computer software
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 8,571	5,311
Computer software | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Computer software | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Hardware development
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Total property and equipment	$ 529	1,024
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Useful life (in years)	7 years
Total property and equipment	$ 0	539
Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful life (in years)	2 years
Total property and equipment	$ 0	$ 748

Composition of certain financ_5

Composition of certain financial statement captions - Narrative (Details) - USD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Depreciation	$ 17,988,000	$ 14,985,000	$ 9,770,000
Property and equipment, at cost	27,813,000	27,310,000
Assets under finance lease, accumulated amortization	20,657,000	15,025,000
Capitalized cost of computer software	23,604,000	12,830,000	7,663,000
Capitalized computed software amortization	5,945,000	5,664,000	5,884,000
Amortization of intangible assets	1,371,000	653,000	254,000
Impairment of goodwill	0	0	0
Goodwill adjustments during the year	115,000
Capitalized implementation costs	1,532,000,000
Capitalized implementation costs, accumulated amortization	610,000,000
Other (expense) income, net	$ (175,000)	(78,000)	$ 1,000
QueueDr
Finite-Lived Intangible Assets [Line Items]
Goodwill adjustments during the year		$ 96,000
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	2 years 8 months 12 days	3 years 6 months
Customer relationship
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	8 years 3 months 18 days	9 years 2 months 12 days
License
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period (in years)	13 years 9 months 18 days	14 years 9 months 18 days
Computer equipment
Finite-Lived Intangible Assets [Line Items]
Property and equipment, at cost	$ 27,813,000	$ 27,310,000
Assets under finance lease, accumulated amortization	$ 20,657,000	$ 15,025,000

Composition of certain financ_6

Composition of certain financial statement captions - Schedule of intangible assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 13,950	$ 13,950
Less accumulated amortization	(2,549)	(1,178)
Net carrying value	$ 11,401	12,772
Acquired technology
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	5 years
Total intangible assets, gross carrying value	$ 1,410	1,410
Customer relationship
Finite-Lived Intangible Assets [Line Items]
Total intangible assets, gross carrying value	$ 6,340	6,340
Customer relationship | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	7 years
Customer relationship | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	10 years
License
Finite-Lived Intangible Assets [Line Items]
Useful life (in years)	15 years
Total intangible assets, gross carrying value	$ 6,200	$ 6,200

Composition of certain financ_7

Composition of certain financial statement captions - Schedule of future amortization expense (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]
2024	$ 1,358
2025	1,273
2026	1,242
2027	949
Thereafter	6,579
Net carrying value	$ 11,401	$ 12,772

Composition of certain financ_8

Composition of certain financial statement captions - Schedule of goodwill roll-forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Goodwill [Roll Forward]
Goodwill balance at beginning of period	$ 33,621	$ 8,307
Goodwill additions during the year		25,314
Measurement period adjustments to goodwill during the year	115
Goodwill balance at end of period	$ 33,736	$ 33,621

Composition of certain financ_9

Composition of certain financial statement captions - Schedule of accounts receivable (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Composition Of Certain Financial Statement [Abstract]
Billed	$ 51,458	$ 40,733
Unbilled	989	392
Total accounts receivable, gross	52,447	41,125
Less accounts receivable allowances	(1,053)	(863)	$ (699)
Total accounts receivable	$ 51,394	$ 40,262

Composition of certain finan_10

Composition of certain financial statement captions - Schedule of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Allowance for doubtful accounts at beginning of period	$ 863	$ 699
Bad debt expense	587	212
Write-offs and adjustments	(397)	(48)
Allowance for doubtful accounts at end of period	$ 1,053	$ 863

Composition of certain finan_11

Composition of certain financial statement captions - Schedule of prepaid and other current assets (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Composition Of Certain Financial Statement [Abstract]
Prepaid software and business systems	$ 3,426	$ 3,738
Prepaid data center expenses	2,389	3,230
Prepaid insurance	1,552	1,924
Other prepaid expenses and other current assets	3,342	2,151
Total prepaid and other current assets	$ 10,709	$ 11,043

Revenue and Contract Costs - Na

Revenue and Contract Costs - Narrative (Details) - USD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Revenue from External Customer [Line Items]
Settlement period (in days)	2 days
Capitalized contract cost, amortization	$ 1,696,000	$ 2,211,000	$ 2,025,000
Capitalized contract cost, impairment loss	$ 0	0
Minimum
Revenue from External Customer [Line Items]
Settlement period (in days)	1 day
Capitalized contract cost, amortization period (in years)	3 years
Maximum
Revenue from External Customer [Line Items]
Settlement period (in days)	2 days
Capitalized contract cost, amortization period (in years)	5 years
Subscription and related services
Revenue from External Customer [Line Items]
Lease income	$ 10,197,000	$ 6,489,000	$ 6,312,000

Revenue and Contract Costs - Ro

Revenue and Contract Costs - Rollforward of contract assets and contract liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Contract With Customer Asset [Roll Forward]
Beginning balance - Contract assets (unbilled accounts receivable)	$ 392	$ 1,287
Amount transferred to receivables from beginning balance of contract assets	(392)	(1,287)
Increases in contract assets due to acquisitions	0	243
Contract asset additions, net of reclassification to receivables	989	149
Ending balance - Contract assets (unbilled accounts receivable)	989	392
Contract With Customer Liability [Roll Forward]
Beginning balance - Contract liabilities (deferred revenue)	16,558	10,838
Revenue recognized that was included in deferred revenue at the beginning of the period	(16,005)	(10,838)
Increases in deferred revenue due to acquisitions	0	2,372
Other current year activity in deferred revenue	17,260	14,186
Ending balance - Contract liabilities (deferred revenue)	$ 17,813	$ 16,558

Revenue and Contract Costs - Sc

Revenue and Contract Costs - Schedule of deferred contract acquisition costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Capitalized Contract Cost [Roll Forward]
Capitalized contract costs at beginning of period	$ 4,079	$ 2,941
Additions to deferred contract acquisition costs	427	3,349
Amortization of deferred contract acquisition costs	(1,696)	(2,211)	$ (2,025)
Capitalized contract costs at end of period	2,810	4,079	2,941
Deferred contract acquisition costs, current (to be amortized in next 12 months)	1,056	1,642
Deferred contract acquisition costs, non-current	1,754	2,437
Total deferred contract acquisition costs	$ 2,810	$ 4,079	$ 2,941

Finance leases and other debt -

Finance leases and other debt - Schedule of outstanding loan balances (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Debt Instrument [Line Items]
Finance leases	$ 7,651	$ 12,884
Long-term debt	246
Total finance lease liabilities and other debt	7,897	13,244
Less - current portion of finance lease liabilities and other debt	(5,172)	(5,821)
Long-term finance leases and other debt	2,725	7,423
Financing arrangements
Debt Instrument [Line Items]
Long-term debt	46	266
Accrued interest and payments
Debt Instrument [Line Items]
Long-term debt	$ 200	$ 94

Finance leases and other debt_2

Finance leases and other debt - Amended and restated loan and security agreement (Details) - USD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2021	Mar. 28, 2022	Mar. 27, 2022	Jan. 31, 2022	May 05, 2020	Feb. 28, 2019
Term loan
Debt Instrument [Line Items]
Debt instrument, face amount							$ 20,000,000
Loss on extinguishment of debt		$ 1,073,000
Second SVB Facility | Revolving credit facility
Debt Instrument [Line Items]
Line of credit borrowing capacity						$ 50,000,000
Accordion feature, potential new maximum borrowing capacity						65,000,000
Long term debt	$ 0				$ 0	$ 20,663,000
Third SVB Facility | Revolving credit facility
Debt Instrument [Line Items]
Line of credit borrowing capacity			$ 100,000	$ 50,000
Stated interest rate (as a percent)	3.25%
Interest rate (as a percent)	7%
Annual commitment fee	$ 250,000
Unused capacity, commitment fee (as a percent)	0.15%
Remaining borrowing capacity	$ 100,000,000
Termination fee percentage (up to) (as a percent)						1.50%
Third SVB Facility | Revolving credit facility | Prime Rate
Debt Instrument [Line Items]
Scheduled reduction in interest rate (as a percent)	0.50%

Finance leases and other debt_3

Finance leases and other debt - Schedule of long-term debt maturities (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Total
2024	$ 5,172
2025	2,518
2026	207
Total maturities of finance leases and other debt	7,897
Finance Leases
2024	4,926
2025	2,518
2026	207
Total finance lease liabilities	7,651	$ 12,884
Other Debt
2024	246
2025	0
2026	0
Total long-term debt maturities	$ 246

Finance leases and other debt_4

Finance leases and other debt - Schedule of interest income (expense), net (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Debt Disclosure [Abstract]
Interest expense	$ (1,411)	$ (1,163)	$ (1,695)
Interest income	2,475	79	122
Interest income (expense), net	$ 1,064	$ (1,084)	$ (1,573)

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	Apr. 12, 2021	Jan. 31, 2023	Jan. 31, 2022	Jul. 22, 2019
Class of Stock [Line Items]
Common stock authorized (up to) (in shares)		500,000,000	500,000,000	500,000,000
Common stock par value		$ 0.01	$ 0.01	$ 0.01
Follow-on Offering
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs (in shares)	5,175,000
Issue price per share (in dollars per share)	$ 50

Equity-based compensation - Nar

Equity-based compensation - Narrative (Details) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Jan. 02, 2023	Jan. 01, 2021	Dec. 31, 2020	Jun. 30, 2019 shares	Jan. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022	Jan. 31, 2022 USD ($) offering_period $ / shares shares	Jan. 31, 2021 USD ($) $ / shares shares	Jan. 31, 2018 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair market value of grants (in USD per share) | $ / shares					$ 26.79		$ 46.60	$ 32.78
Intrinsic value					$ 6,970		$ 73,624	$ 33,575
Unrecognized compensation cost to stock option					45
Issuance of common stock for employee stock purchase plan					3,472		$ 1,506
Share settled bonuses					8,812
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, employee common stock purchase discount (as a percent)							15%
Unrecognized compensation costs					$ 605
Weighted average term for recognition (in years)					5 months
Employee purchase price of common stock (as a percent)					85%
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)			7 years
Unrecognized compensation costs					$ 112,482
Weighted average term for recognition (in years)					2 years 9 months 18 days
Bonus settlement in shares (as a percent)					115%
Awards vested during period (in shares) | shares					1,626,679		559,767	242,049
RSUs | Employees Other than NEOs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)		4 years
Quarterly vesting rate (as a percent)		6.25%
RSUs | NEOs and Other Members of Executive Management
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)	4 years					4 years
Quarterly vesting rate (as a percent)	25%					6.25%
RSUs | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)			10%
Vesting term (in years)			1 year
RSUs | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)			20%
Vesting term (in years)			2 years
RSUs | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)			30%
Vesting term (in years)			3 years
RSUs | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)			40%
Vesting term (in years)			4 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting term (in years)					4 years
Weighted average term for recognition (in years)					3 months 29 days
Expiration period / maximum term (in years)					10 years
Incremental expense associated with the modification of stock options					$ 322
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					100%
Vesting term (in years)					3 years
Unrecognized compensation costs					$ 26,128
Weighted average term for recognition (in years)					2 years 4 months 24 days
Weighted average fair market value of grants (in USD per share) | $ / shares					$ 56.52		$ 48.47	$ 84.38
Awards vested during period (in shares) | shares					0		0
PSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					0%
PSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					220%		200%	200%
2018 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for issuance (in shares) | shares									3,048,490
2019 Stock Option And Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserve for future issuance (in shares) | shares				2,139,683
Percentage increase in number of shares reserved (as a percent)				5%
2019 Stock Option And Incentive Plan | ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant (in shares) | shares				855,873	3,408,720
Additional shares authorized (in shares) | shares							576,304
ESPP, number of offering periods per year | offering_period							2
ESPP offering period (in months)							6 months
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					25%
Vesting term (in years)					1 year
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					25%
Vesting term (in years)					1 year
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					25%
Vesting term (in years)					1 year
2019 Stock Option And Incentive Plan | Stock options | Share-based Payment Arrangement, Year 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vest option (as a percent)					25%
Vesting term (in years)					1 year
2022 Share Settled Bonus Award Program | RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards vested during period (in shares) | shares					302,931

Equity-based compensation - Sto

Equity-based compensation - Stock-based compensation (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	$ 60,147	$ 36,723	$ 13,489
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	42,214	24,222	10,693
Liability awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	7,641	7,055	0
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	7,282	2,389	93
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	1,489	2,294	2,703
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation	$ 1,521	$ 763	$ 0

Equity-based compensation - S_2

Equity-based compensation - Stock-based compensation in our financial statements (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 60,147	$ 36,723	$ 13,489
Less stock-based compensation expense capitalized as internal-use software	(1,372)	(489)	0
Stock-based compensation expense	58,775	36,234	13,489
Non-cash stock-based compensation expense	58,775	36,144	13,489
Cash settled stock based compensation expense		90
Additional paid-in capital
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	52,506	29,668	13,489
Accrued expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 7,641	$ 7,055	$ 0

Equity-based compensation - Per

Equity-based compensation - Performance-based restricted stock units (Details) - shares	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
RSUs
Restricted Stock Unit Activity:
Beginning balance (in shares)	3,133,839	2,053,038	1,447,418
Granted (in shares)	2,907,838	1,836,534	972,271
Vested (in shares)	(1,626,679)	(559,767)	(242,049)
Forfeited and expired (in shares)	(497,245)	(195,966)	(124,602)
Ending balance (in shares)	3,917,753	3,133,839	2,053,038
PSUs
Restricted Stock Unit Activity:
Beginning balance (in shares)	396,216	70,806	0
Granted (in shares)	255,572	325,410	70,806
Vested (in shares)	0	0
Forfeited and expired (in shares)	(3,555)	0
Ending balance (in shares)	648,233	396,216	70,806

Equity-based compensation - Val

Equity-based compensation - Valuation allowance of performance-based restricted stock units (Details)	12 Months Ended
	Jan. 31, 2023 $ / shares	Jan. 31, 2022 $ / shares	Jan. 31, 2021 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair market value of grants (in USD per share)	$ 26.79	$ 46.60	$ 32.78
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Correlation coefficient	0.4957	0.3878	0.4230
Valuation date stock price (in USD per share)	$ 35.41	$ 36.03	$ 62.96
Simulation term (in years)	3 years	2 years 11 months 26 days	3 years
Volatility (as a percent)	64.98%	44.32%	43.71%
Risk-free rate (as a percent)	3.84%	1.23%	0.20%
Dividend yield (as a percent)	0%	0%	0%
Weighted average fair market value of grants (in USD per share)	$ 56.52	$ 48.47	$ 84.38

Equity-based compensation - Wei

Equity-based compensation - Weighted average assumptions (Details) - ESPP	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (as a percent)	3.68%	0.17%
Expected dividends (as a percent)	0%	0%
Expected term (in years)	5 months 19 days	5 months 26 days
Volatility (as a percent)	74.80%	55.70%

Equity-based compensation - S_3

Equity-based compensation - Stock option activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Number of options
Number of options outstanding at beginning of period (in shares)	1,705,150	3,211,354	5,516,452
Granted (in shares)	0	0	0
Exercised (in shares)	(311,743)	(1,439,186)	(2,216,368)
Forfeited and expired (in shares)	(8,214)	(67,018)	(88,730)
Number of options outstanding at end of period (in shares)	1,385,193	1,705,150	3,211,354
Exercisable (in shares)	1,362,903
Amount vested at the end of the period (in shares)	258,735
Weighted- average exercise price
Weighted- average exercise price outstanding at beginning of period (in dollars per share)	$ 6.01	$ 4.67	$ 3.80
Granted (in dollars per share)	0	0	0
Exercised (in dollars per share)	4.92	2.88	2.39
Forfeited and expired (in dollars per share)	4.68	9.02	7.45
Weighted- average exercise price outstanding at end of period (in dollars per share)	6.26	$ 6.01	$ 4.67
Exercisable (in dollars per share)	6.12
Amount vested at the end of the period (in dollars per share)	$ 8.27
Weighted-average remaining contractual life of options outstanding and expected to vest (in years)	5 years 21 days	5 years 11 months 8 days	5 years 11 months 26 days
Weighted-average remaining contractual life of options exercisable (in years)	5 years 10 days
Aggregate intrinsic value outstanding and expected to vest	$ 43,341	$ 42,938	$ 194,676
Aggregate intrinsic value exercisable	$ 42,750

Fair value measurements - Sched

Fair value measurements - Schedule of assets and liabilities measured at fair value (Details) - Fair value, recurring - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	$ 163,563	$ 197,601
Total assets	163,563	197,601
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	163,563	197,601
Total assets	163,563	197,601
Significant Other Observable Inputs (Level 2)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	0	0
Total assets	0	0
Significant Unobservable Inputs (Level 3)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Money market mutual funds	0	0
Total assets	$ 0	$ 0

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease, weighted average remaining lease term (in years)	1 year 7 months 6 days
Operating lease, weighted average discount rate (as a percent)	3.50%
Finance lease, weighted average remaining lease term (in years)	1 year 7 months 6 days
Finance lease, weighted average discount rate (as a percent)	3.60%
Purchase obligation	$ 8,115
Subscription and related services
Lessee, Lease, Description [Line Items]
Lease income	10,197	$ 6,489	$ 6,312
Computer equipment
Lessee, Lease, Description [Line Items]
Purchase obligation	$ 8,058
Computer equipment | Minimum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	2 years
Computer equipment | Maximum
Lessee, Lease, Description [Line Items]
Finance lease, term of contract (in years)	3 years

Leases - Schedule of operating

Leases - Schedule of operating and finance leases (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Leases [Abstract]
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively	Property and equipment, net of accumulated depreciation and amortization of $59,847 and $53,321 as of January 31, 2023 and 2022, respectively
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Long-Term Debt and Lease Obligation, Current	Long-Term Debt and Lease Obligation, Current
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Long-term finance leases and other debt	Long-term finance leases and other debt
Operating leases:
Lease right-of-use assets	$ 569	$ 2,337
Lease liabilities, current	934	1,281
Lease liabilities, non-current	349	1,276
Total operating lease liabilities	1,283	2,557
Finance leases:
Property and equipment, at cost	27,813	27,310
Accumulated depreciation	(20,657)	(15,025)
Property and equipment, net	7,156	12,285
Lease liabilities, current (included in Current portion of finance lease liabilities and other debt)	4,926	5,600
Lease liabilities, non-current (included in Long-term finance lease liabilities and other debt)	2,725	7,284
Total finance lease liabilities	$ 7,651	$ 12,884

Leases - Schedule of lease expe

Leases - Schedule of lease expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Operating leases:
Operating lease cost	$ 1,835	$ 1,096	$ 1,766
Variable lease cost	62	223	257
Total operating lease cost	1,897	1,319	2,023
Finance leases:
Amortization of right-of-use assets	5,632	4,636	2,876
Interest on lease liabilities	368	378	326
Total finance lease cost	$ 6,000	$ 5,014	$ 3,202

Leases - Schedule of maturing l

Leases - Schedule of maturing lease payments (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Operating
2024	$ 958
2025	225
2026	86
2027	42
Thereafter	7
Total future minimum lease payments	1,318
Less: interest	(35)
Total operating lease liabilities	1,283	$ 2,557
Finance
2024	5,102
2025	2,566
2026	209
2027	0
Finance Lease, Liability, to be Paid, After Year Four	0
Total future minimum lease payments	7,877
Less: interest	(226)
Finance leases	$ 7,651	$ 12,884

Leases - Schedule of supplement

Leases - Schedule of supplemental cash flow information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash used for operating leases	$ 1,347	$ 1,206	$ 1,629
Operating cash used for finance leases	396	377	326
Financing cash used for finance leases	5,731	4,267	2,630
Total cash paid in measurement of lease liabilities	$ 7,474	$ 5,850	$ 4,585

Commitments and contingencies -

Commitments and contingencies - Schedule of aggregate minimum purchase commitments (Details) $ in Thousands	Jan. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2024	$ 11,646
2025	8,115
2026	3,530
2027	598
Total	$ 23,889

Income taxes - Narratives (Deta

Income taxes - Narratives (Details) - USD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ 483,000	$ 182,000	$ 49,000
Effective tax rate (as a percent)	0.30%	0.20%	(0.20%)
Valuation allowance	$ (143,135,000)	$ (97,279,000)
Increase in valuation allowance	45,856,000
Tax examination, penalties and interest accrued	0
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Accumulated federal net operating loss carryforward	493,333,000	$ 332,544,000
Foreign Tax Authority
Operating Loss Carryforwards [Line Items]
Accumulated federal net operating loss carryforward	$ 716,000

Income taxes - Components of ta

Income taxes - Components of tax (benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Current tax
Federal	$ 0	$ 0	$ 0
State	49	39	114
Foreign	0	0	0
Deferred tax
Federal	109	0	(116)
State	0	0	(65)
Foreign	325	143	116
Total provision for income taxes	$ 483	$ 182	$ 49

Income taxes - Effective tax ra

Income taxes - Effective tax rate reconciliation (Details)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rate (as a percent)	21%	21%	21%
State and local tax, net of federal benefit (as a percent)	5%	9%	10%
Permanent differences (as a percent)	0%	0%	0%
Equity compensation (as a percent)	0%	6%	44%
Foreign taxes (as a percent)	0%	0%	0%
Other (as a percent)	0%	0%	(4.00%)
Change in valuation allowance (as a percent)	(26.00%)	(36.00%)	(71.00%)
Effective income tax rate (as a percent)	0.30%	0.20%	(0.20%)

Income taxes - Company's deferr

Income taxes - Company's deferred tax assets and deferred tax liabilities (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022
Deferred tax assets
Net operating loss carryforwards	$ 131,574	$ 88,979
Stock based compensation	7,765	5,374
Accruals, reserves, and other expenses	2,763	3,697
Reserve for bad debts	530	521
Disallowed interest expense	1,934	1,934
Total deferred tax assets	144,566	100,505
Valuation allowance	143,135	97,279
Net deferred tax assets	1,431	3,226
Depreciation and amortization	(295)	(1,250)
Intangible assets	(305)	(373)
Deferred contract acquisition costs	(750)	(1,088)
Total deferred tax liabilities	(1,350)	(2,711)
Deferred taxes, net	$ 81	$ 515

Net loss per share attributab_3

Net loss per share attributable to common stockholders - Schedule of computation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Numerator:
Net loss	$ (176,146)	$ (118,161)	$ (27,292)
Denominator:
Weighted-average common shares outstanding - basic (in shares)	52,440,067	49,888,436	39,519,640
Weighted-average common shares outstanding - diluted (in shares)	52,440,067	49,888,436	39,519,640
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ (3.36)	$ (2.37)	$ (0.69)
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ (3.36)	$ (2.37)	$ (0.69)

Net loss per share attributab_4

Net loss per share attributable to common stockholders - Schedule of antidilutive securities (Details) - shares	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,820,276	5,708,193	5,406,004
Stock options to purchase common stock, restricted stock units and performance stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	6,745,591	5,632,823	5,406,004
Employee stock purchase plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	74,685	75,370	0

Retirement savings plan (Detail

Retirement savings plan (Details) - USD ($)	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Retirement Benefits [Abstract]
Company contributions	$ 0	$ 0	$ 0

Related party transactions (Det

Related party transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Advertisements with Pharmaceutical Company | Affiliate of Director
Related Party Transaction [Line Items]
Recognized revenue from related parties	$ 775	$ 482
Accounts receivable from related parties	339	173
Software Agreement | Affiliate of Director
Related Party Transaction [Line Items]
General and administrative expenses from transactions with related party	374	182
Software Agreement | Affiliate of Director | Prepaid and other current assets
Related Party Transaction [Line Items]
Due from related parties, current	$ 51	374
Software Agreement | Affiliate of Director | Other assets
Related Party Transaction [Line Items]
Due from related parties, noncurrent		$ 51
Revenue from Affiliate of Stockholder | Affiliated Entity
Related Party Transaction [Line Items]
Recognized revenue from related parties			$ 2,425

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Thousands			12 Months Ended
	Dec. 03, 2021	Jan. 08, 2021	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Business Acquisition [Line Items]
Change in fair value of contingent consideration liabilities			$ 0	$ 258	$ 0
Insignia
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)	100%
Consideration transferred	$ 37,208
Weighted average amortization period (in years)		13 years
Acquisition related costs				720
QueueDr
Business Acquisition [Line Items]
Percentage of equity acquired (as a percent)		100%
Consideration transferred		$ 10,124
Acquisition related costs					$ 282
Acquisition related costs incurred				258
Change in fair value of contingent consideration liabilities				$ 1,544

Acquisitions - Schedule of Insi

Acquisitions - Schedule of Insignia Health, LLC and QueueDr purchase price consideration (Details) - USD ($) $ in Thousands	Dec. 03, 2021	Jan. 08, 2021
Insignia
Business Acquisition [Line Items]
Cash consideration paid on acquisition date	$ 37,112
Liabilities incurred	96
Total fair value of acquisition consideration	$ 37,208
QueueDr
Business Acquisition [Line Items]
Cash consideration paid on acquisition date		$ 5,773
Liabilities incurred		2,111
Contingent consideration		2,240
Total fair value of acquisition consideration		$ 10,124

Acquisitions - Schedule of cons

Acquisitions - Schedule of consideration paid (Details) - USD ($) $ in Thousands			12 Months Ended
	Dec. 03, 2021	Jan. 08, 2021	Jan. 31, 2023	Jan. 31, 2022	Jan. 31, 2021
Business Acquisition [Line Items]
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows			$ 0	$ 34,423	$ 6,510
Insignia
Business Acquisition [Line Items]
Cash consideration paid on acquisition date	$ 37,112
Less cash acquired	(2,689)
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows	$ 34,423
QueueDr
Business Acquisition [Line Items]
Cash consideration paid on acquisition date		$ 5,773
Payments of acquisition date fair value of contingent consideration		954
Less cash acquired		(217)
Cash paid for acquisition of QueueDr, net of cash acquired per statement of cash flows		$ 6,510

Acquisitions - Schedule of fina

Acquisitions - Schedule of final allocation of Insignia Health purchase price (Details) - USD ($) $ in Thousands	Jan. 31, 2023	Jan. 31, 2022	Dec. 03, 2021	Jan. 31, 2021
Business Acquisition [Line Items]
Goodwill	$ 33,736	$ 33,621		$ 8,307
Insignia
Business Acquisition [Line Items]
Cash			$ 2,689
Accounts receivable			994
Prepaid expenses and other assets			358
Operating lease right-of-use assets			606
Intangibles			10,700
Goodwill			25,410
Total assets acquired			40,757
Accounts payable			(84)
Accrued liabilities			(487)
Deferred revenue			(2,372)
Operating lease liabilities			(606)
Total purchase price			$ 37,208

Acquisitions - Schedule of inta

Acquisitions - Schedule of intangible asset acquired related to Insignia Health acquisition (Details) - USD ($) $ in Thousands		12 Months Ended
	Dec. 03, 2021	Jan. 31, 2023
License
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)		15 years
Insignia
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value	$ 10,700
Insignia | License
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	15 years
Fair Value	$ 6,200
Insignia | Customer relationship
Acquired Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life (in Years)	10 years
Fair Value	$ 4,500

Subsequent event (Details)

Subsequent event (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2023	Mar. 10, 2023	Jan. 31, 2022	Jan. 31, 2021	Jan. 31, 2020
Subsequent Event [Line Items]
Cash and cash equivalents	$ 176,683		$ 313,812	$ 218,781	$ 90,315
Third SVB Facility
Subsequent Event [Line Items]
Number of months with sufficient funds to operate (in months)	12 months
Subsequent event | Third SVB Facility
Subsequent Event [Line Items]
Cash and cash equivalents		$ 170,000
Subsequent event | Third SVB Facility | Revolving credit facility
Subsequent Event [Line Items]
Allowable cash hold outside of facility		$ 165,000